CURRICULUM VITAE

Dr. Prashant Kesharwani
USERN Laurates,
Assistant Professor & Ramanujan Fellow,
Department of Pharmaceutics,
School of Pharmaceutical Education and Research,
Jamia Hamdard (A Government-aided Deemed University)
An Institution of Eminence (IoE) declared by GOI
New Delhi, INDIA-110062
Mob: +91-7999710141, +91-7582-244432
Date of Birth: 04th October 1984
E-mail : prashantdops@gmail.com ; drprashantpharm@gmail.com

EDUCATION:

PhD, Pharmaceutics, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar (M.P.), India 2014.

M. Pharma., Pharmaceutics, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar (M.P.), India 2009.

B. Pharma., Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar (M.P.), India 2007.

PROFESSIONAL EXPERIENCE:

December 2018-Till date	**Assistant Professor**, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed to be University), New Delhi, INDIA-110062
April 2017-December 2018	**SERB Ramanujan Fellow**, CSIR-Central Drug Research Institute (CDRI), Lucknow, 226031, U.P., India
September 2016- April 2017	**Lecturer**, School of Pharmacy, Department of Pharmaceutical Technology, International Medical University (IMU), Kuala Lumpur, **Malaysia**
September 2014-July 2016	**Postdoctoral Fellow**, Department of Pharm. Sciences, Eugene Applebaum College of Pharmacy and Health Sciences; Wayne State University, Detroit (MI) **USA**
January 2012-August 2014	**ICMR-SRF**, Dr. Hari Singh Gour Central University, Sagar (M.P.), India
October 2010-January 2012	**Guest faculty**, Dr. Hari Singh Gour Central University, Sagar (M.P.), India
January 2010-July 2010	**Management Trainee**, Indoco Remedies Ltd. Navi Mumbai, India
June 2007-August 2007	**Lecturer**, Adina Institute of Pharmaceutical Sciences, Sagar M.P

RESEARCH GRANT:

1. **ICMR Extramural project]: [Jamia Hamdard, New Delhi]**
   PI: Dr Prashant Kesharwani Duration: April 2019-March 2022
   Title: Survivin siRNA targeted poly(propylene imine) dendrimer loaded with doxorubicin and lycopene against triple negative breast cancer
   Budget: 37 Lac

2. **[SERB Ramanujan fellowship]: [CSIR-CDRI Lucknow & Jamia Hamdard, New Delhi]**
   PI: Dr Prashant Kesharwani Duration: April 2017- March 2020
   Title: Aptamer anchored smart multifunctional dendrimer-BSA nanoarchitectures for the effective treatment of drug resistant non-small cell lung cancer
   Budget: 53.40 Lac

3. **[UGC start up grant]: [Jamia Hamdard, New Delhi]**
   PI: Dr Prashant Kesharwani Duration: September 2019- August 2021
   Title: RGD-engineered poly (propylene imine) dendrimers conjugated to iron oxide nanoparticles for targeted tumor magnetic resonance imaging (MRI)
   Budget: 10 Lac

4. **[ICMR Extramural project]: [Jamia Hamdard, New Delhi]**
   PI: Dr Prashant Kesharwani Duration: April 2020-March 2023
   Title: Aptamer engineered smart multifunctional dendrimer-BSA nano-architectures targeting stem cell marker CD133 for triple-negative breast cancer therapy
   Budget: 35 Lac

5. **[ICMR Extramural project]: [Jamia Hamdard, New Delhi]**
   PI: Dr Prashant Kesharwani Duration: March 2022-February 2025
   Title: Cell death inducing targeted therapy enhanced by amphiphilic co-block polymeric nanoscale drug delivery tool for triple-negative breast cancer therapy
   Budget: 37 Lac

6. **[ICMR Extramural project]: [Jamia Hamdard, New Delhi]**
   PI: Dr Prashant Kesharwani Duration: March 2022-February 2025
   Title: Strategic viral-mimicking, DNA-ejecting polyplex as a novel nanotherapeutic tool for breast cancer therapy
   Budget: 35.18 Lac

PROFESSIONAL RECOGNITION, AWARDS, FELLOWSHIPS RECEIVED:

1. Selected as the international "***USERN LAUREATE"*** for the year 2023 (***World's Best Scientist below 40 years***) in the biological sciences (5000 USD cash price). First Inidan received this award (10th November 2023 at Yerevan, Armenia) on 8th USERN Congress and Prize Awarding Festival [***among more than 90,000 applications from all over the world and applications have been carefully reviewed by more than 70 top 1% well-known scientists***].
2. Listed in the "***WORLD'S TOP 2% SCIENTISTS***" list 2022 in the field of "Pharmacology & Pharmacy" published by Stanford University.
3. Listed in the "***WORLD'S TOP 2% SCIENTISTS***" list 2021 in the field of "Pharmacology & Pharmacy" published by Stanford University.

4. Careers360 "***Faculty Research Award***" for the Most Outstanding Researcher in the country in the field of Medicine (6th October 2023).
5. Third position on poster presentation in the Graduate and Postdoctoral Research Symposium (23 March 2016) at Wayne State University, Graduate school, Detroit, MI, USA (**INTERNATIONAL**).
6. Awarded most prestigious "***SERB-RAMANUJAN FELLOWSHIP***".
7. I am the only candidate who has joined Jamia Hamdard with 5 advanced salary increments.
8. Young Innovator Award (Gold medal) in 1st International Conferences on Innovative Pharmacy & Pharmaceutical Sciences 2012 (ICIPPS-2012).
9. Awarded first position on oral presentation in the DST & DBT sponsored national seminar on "Nanobiotechnology" (2013) at Guru Ramdas Khalsa, Institute of Science & Technology, (M.P.).
10. Awarded "Excellence Research Award" (2014) second position in the MPCST sponsored national seminar at Adina Institute of Pharmaceutical Sciences, Sagar (M.P.)
11. Awarded "fellowship for training of Young Scientist" (2014-15) of M.P. Council of Science and Technology at the 29th M.P. Young Scientist Congress.
12. Awarded twice "fellowship for training of Young Scientist" (2013-14) of M.P. Council of Science and Technology at the 28th M.P. Young Scientist Congress.
13. International Travel Award from DST (New Delhi) 2012
14. International Travel Grant from INSA (CCSTDS, Chennai) 2012
15. International Travel Award/Grant from CSIR (New Delhi) 2018.
16. Awarded ICMR-SRF fellowship for pursuing PhD 2012.
17. Awarded AICTE-JRF fellowship for pursuing M. Pharma 2007.

PUBLICATION DETAILS:

Total number of publications	**:**	**558**
Research / Review articles	**:**	**446**
Book published as Editor	**:**	**29**
Book chapters	**:**	**83**
Cumulative impact factor	**:**	**4496.217**
Total citations	**:**	**22784**
h-index	**:**	**79**
i-10 index	**:**	**329**



https://scholar.google.co.in/citations?user=DJkvOAQAAAAJ&hl=en

Year 2010:

1. Jain K, **Kesharwani P**, Gupta U, Jain NK. Dendrimer toxicity: Let's meet the challenge. Int J Pharm. 2010;394(1-2):122-42. https://doi.org/10.1016/j.ijpharm.2010.04.027 **(Impact factor 5.875)**
2. Kothule KU, **Kesharwani P**, Gidwani SK. Synthesis and biological evaluation of some schiffs bases of 2-substituted- 1, 3, 4-Oxadiazole. Asian J Res Chem. March 2010;3(4):1-3.

3. Kothule KU, **Kesharwani P**, Gidwani SK, Gide P. Development and characterization of chitosan nanoparticles and improvement of oral bioavailability of poorly water soluble acyclovir. Research J. Pharm. and Tech. Oct 2010;3(4): 1-5.

Year 2011:

4. **Kesharwani P**, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7(3):295-304. https://doi.org/10.1016/j.nano.2010.10.010 **(Impact factor 6.692)**
5. **Kesharwani P**, Jain K, Tekade RK, Gajbhiye V, Jain NK. Spectrophotometric estimation of paclitaxel. Int J Adv Pharm Sci 2011;2:29-32.
6. **Kesharwani P**, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. Curr Drug Targets. 2011;12(10):1478-97. **(Impact factor 4.27)**

Year 2012:

7. Dubey M, **Kesharwani P**, Tiwari A, Chandel R, Raja K, Sivakumar T. Formulation and evaluation of floating microsphere containing anti diabetic drug. Int. J. Pharm. Chem Sci. 2012;1:1038-47.
8. **Kesharwani P**, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. Oct 2012;33(29):7138-50. 10.1016/j.biomaterials.2012.06.068 **(Impact factor 14)**
9. **Kesharwani P**, Ghanghoria R, Jain NK. Carbon nanotube exploration in cancer cell lines. Drug Discov Today. 2012;17(17-18):1023-30. https://doi.org/10.1016/j.drudis.2012.05.003 **(Impact factor 7.851)**
10. Jain K, **Kesharwani P**, Gupta U, Jain NK. A review of glycosylated carriers for drug delivery. Biomaterials. 2012;33(16):4166-86. https://doi.org/10.1016/j.biomaterials.2012.02.033 **(Impact factor 14)**

Year 2013:

11. Thakur S, **Kesharwani P**, Tekade RK, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers. J Nanopart Res. April 2013;15:1625. **(Impact factor 2.5)**
12. Ghanghoria R, **Kesharwani P**, Agashe HB, Jain NK. Transdermal delivery of cyclodextrin-solubilized curcumin. Drug Deliv. and Transl. Res. June 2013;3:272-85. **(Impact factor 4.617)**
13. Jain A, Jain K, **Kesharwani P**, Jain NK. Low density lipoproteins mediated nanoplatforms for cancer targeting. J Nanopart Res (2013) 15:1888. **(Impact factor 2.5)**

Year 2014:

14. **Kesharwani P**, Tekade RK, Jain NK. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials. July 2014;35(21):5539-48. **(Impact factor 14)**
15. **Kesharwani P**, Tekade RK, Jain NK. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond). Feb 2014;9(15):2291-308. **(Impact factor 5.824)**
16. **Kesharwani P**, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci, Feb 2014;39:268-307. **(IMPACT FACTOR 29.190)**
17. Mishra V, **Kesharwani P**, Jain NK. siRNA nanotherapeutics: a Trojan horse approach against HIV. Drug Discov Today. Dec 2014;19(12):1913-20. **(Impact factor 7.851)**

Year 2015:

18. **Kesharwani P**, Tekade RK, Jain NK. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm Res. April 2015;32(4):1438-50. **(Impact factor 4.200)**

19. **Kesharwani P**, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Parenterally administrable nano-micelles of Difluorobenzylidene curcumin difluorinated for treating pancreatic cancers. Colloids Surf. B Biointerfaces, Aug 2015;132:138–45. **(Impact factor 5.8)**
20. **Kesharwani P**, Xie L, Maob G, Padhye S, Iyer AK. Hyaluronic acid-conjugated polyamidoamine dendrimers for CD44 target mediated 3,4-difluorobenzylidene curcumin delivery for treating pancreatic cancer. Colloids Surf. B Biointerfaces, Dec 2015;136:413-23. **(Impact factor 5.8)**
21. **Kesharwani P**, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid engineered nano-micelles loaded with 3, 4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromolecules, Aug 2015;16:3042–53. **(Impact factor 6.988)**
22. **Kesharwani P**, Mishra V, Jain NK. Generation dependent hemolytic profile of folate engineered poly(propyleneimine) dendrimer. J. Drug Deliv. Sci. & Tech. Aug 2015;28:1-6. **(Impact factor 5)**
23. Amjad MW, Mohd Amin MCI, Katas H, Butt AM, **Kesharwani P**, Iyer AK. The in vivo anti-tumor activity of folate-conjugated cholic acid-polyethylenimine micelles for the co-delivery of doxorubicin and siRNA to colorectal adenocarcinomas. Molecular Pharmaceutics Dec 2015;12(12):4247-58. **(Impact factor 4.939)**
24. Mansuri S, **Kesharwani P**, Tekade RK, Jain NK. Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. European Journal of Pharmaceutics and Biopharmaceutics, Volume 102, May 2016, Pages 202-213 **(Impact factor 5.571)**
25. Singh R, **Kesharwani P**, Mehra NK, Singh S, Banerjee S, Jain N.K. Development and characterization of Saquinavir entrapped Poly (D, L-Lactide-co-Glycolide) (PLGA) nanoparticles for anti-tumor activity. Drug Dev Ind Pharm. March 2015;41(11):1888-901. **(Impact factor 3.232)**
26. Tiwari A, **Kesharwani P***, Gajbhiye V, Jain NK. Synthesis and characterization of dendro-PLGA nanoconjugate for protein stabilization. Colloids Surf. B Biointerfaces, Oct 2015;134:279-86. **(Impact factor 5.8)**
27. Birdhariya B, **Kesharwani P**, Jain NK. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev Ind Pharm. Aug 2015;41(8):1393-9. **(Impact factor 3.232)**
28. Jain S, **Kesharwani P**, Tekade RK, Jain NK. One platform comparison of solubilization potential of dendrimer with some solubilizing agents. Drug Dev Ind Pharm. March 2015;41(5):722-7. **(Impact factor 3.232)**
29. **Kesharwani P**, Iyer AK, Banerjee S, Gupta U, MCI Mohd Amin, Sarkar FH, Padhye S. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Material Today, Dec 2015;18:565–72. **(IMPACT FACTOR: 32.072)**
30. **Kesharwani P***, Mishra V, Jain NK. Validation of carbon nanotubes based nano-therapeutics through cell line testing. Drug Discovery Today, Sep 2015;20:1049-60. **(Impact factor 7.851)**
31. **Kesharwani P**, Tekade RK, Jain NK. Dendrimer generational nomenclature: the need to harmonize. Drug Discov Today, May 2015;20(5):497-9. **(Impact factor 7.851)**
32. **Kesharwani P**, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today, May 2015;20(5):536-547. **(Impact factor 7.851)**
33. Gothwal A, **Kesharwani P***, Gupta U, Khan I, Mohd Amin MCI, Banerjee S, Iyer AK. Dendrimers as an effective nanocarrier in cardiovascular disease. Current Pharm. Design 2015;21:4519-26. **(Impact factor 3.288)**
34. Jain A, **Kesharwani P***, Garg NK, Jain A, Nirbhavane P, Banerjee S, Mohd Amin MCI, Iyer AK. Nano-constructed carriers loaded with antioxidant: Boon for cardiovascular system. Current Pharm. Design. 2015;21:4456-64. **(Impact factor 3.288)**
35. Thakur S, **Kesharwani P***, Tekade RK, Jain NK. Impact of pegylation on biopharmaceutical properties of dendrimers. Polymer, Feb 2015;59:67-92. **(Impact factor 4.430)**

Year 2016:

36. Ng KE, Amin MC, Katas H, Amjad MW, Butt AM, **Kesharwani P**, Iyer AK. pH-responsive triblock copolymeric micelles decorated with a cell-penetrating peptide provide efficient doxorubicin delivery. Nanoscale Res Lett. Dec 2016;11(1):539. **(Impact factor 2.833)**
37. Ghanghoria R, **Kesharwani P**, Tekade RK, Jain NK. Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers. Journal of Controlled Release, Volume 269, 10 January 2018, Pages 277-301 **(Impact factor 9.776)**
38. **Kesharwani P**,[1,*] Jain A, Jain A, Jain AK, Garg NK, Tekade RK, Singh TRR, Iyer AK. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors. RSC Adv. Aug 2016;6:89040-50. **(Impact factor 3.361)**
39. Nag M, Gajbhiye V, **Kesharwani P**, Jain NK. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells. Colloids Surf B Biointerfaces. Dec 2016;148:363-370. **(Impact factor 5.8)**
40. Mahor A, Prajapati SK, Verma A, Gupta R, Iyer AK, **Kesharwani P***. Moxifloxacin loaded gelatin nanoparticles for ocular delivery: Formulation and in-vitro, in-vivo evaluation. J Colloid Interface Sci. Dec 2016;483:132-8. **(Impact factor 8.128)**
41. Patel HK, Gajbhiye V, **Kesharwani P**, Jain NK. Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. J Colloid Interface Sci. Nov 2016;482:142-50. **(Impact factor 8.128)**
42. Mahor A, Prajapati SK, Verma A, Gupta R, Singh TRR, **Kesharwani P***. Development, in-vitro and in-vivo characterization of gelatin nanoparticles for delivery of an anti-inflammatory drug. Journal of Drug Delivery Science and Technology Dec 2016;36:55–61. **(Impact factor 5)**
43. Luong D, **Kesharwani P**, Killinger BA, Moszczynska A, Sarkar FH, Padhye S, Rishi AK, Iyer AK. Solubility enhancement and targeted delivery of a potent anticancer flavonoid analogue to cancer cells using ligand decorated dendrimer nano-architectures. J Colloid Interface Sci. Dec2016;484:33-43. **(Impact factor 8.128)**
44. Deshmukh R, Sharma L, Tekade M, **Kesharwani P**, Trivedi P, Tekade RK. Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. J Biomed Res. March 2016;30(2):149–61.
45. Choudhary S, Jain A, Mohd Amin MCI, Mishra V, Agrawal GP, **Kesharwani P***. Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer. Colloids and Surfaces B: Biointerfaces. March 2016;141:268-277. **(Impact factor 5.8)**
46. Jain A, Garg, NK, Jain A, Jain AK, Nirbhavane P, Tyagi RK, **Kesharwani P**. Synergistic approach of Adapalene-Loaded Nanostructured lipid carriers, vitamin C Co-adminstration for Treating Acne. Drug Dev Ind Pharm. Nov 2016;42(6):897-905. **(Impact factor 3.232)**
47. Butt AM, Amin MCIM, Katas H, Murad A, Azian N, Rahman J, **Kesharwani P**. Doxorubicin and siRNA co-delivery via chitosan-coated pH-responsive mixed micellar polyplexes for enhanced cancer therapy in multidrug-resistant tumors. Mol. Pharmaceutics Oct 2016, 13, 12, 4179–4190 **(Impact factor 4.939)**
48. Soni N, Soni N, Pandey H, Maheshwari R, **Kesharwani P**, Tekade RK. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J Colloid Interface Sci. Nov 2016;481:107-16. **(Impact factor 9.965)**
49. Sharma AK, Gothwal A, **Kesharwani P**, Alsaab H, Iyer AK, Gupta U. Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery. Drug Discov Today. 2016 doi:

10.1016/j.drudis.2016.09.013. Drug Discov Today. 2017 Feb;22(2):314-326. doi: 10.1016/j.drudis.2016.09.013. **(Impact factor 7.851)**.

50. Luong D[1], **Kesharwani P**[1], Deshmukh R, Mohd Amin MC, Gupta U, Greish K, Iyer AK. PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomater. Oct 2016;43:14-29. **(Impact factor 8.947)**
51. Tekade RK, Tekade M, **Kesharwani P**, D'Emanuele A. RNAi-combined nano-chemotherapeutics to tackle resistant tumors. Drug Discovery Today, Volume 21, Issue 11, November 2016, Pages 1761-1774. doi: 10.1016/j.drudis.2016.06.029. **(Impact factor 7.851)**
52. Kaur D, Jain K, Mehra, NK, **Kesharwani P**, Jain NK. A review on comparative study of PPI and PAMAM dendrimers. J Nanopart Res. June 2016:18: 146. doi:10.1007/s11051-016-3423-0. **(Impact factor 2.5)**
53. Shukla A, Mishra V, **Kesharwani P***. Bilosomes in context to oral immunization: need of rigorous exploitation. Drug Discov Today. June 2016;21:888-99. **(Impact factor 7.851)**
54. **Kesharwani P**, Ghanghoria R, Jain NK. Experimental models for evaluation of nanoparticles in cancer therapy. Mini Rev Med Chem. 2017;17(18):1725-1745. **(Impact factor 3.862)**
55. Ghanghoria R, **Kesharwani P**, Jain NK. Significance of various experimental models and assay techniques in cancer diagnosis. Mini Rev Med Chem. 2017;17(18):1713-1724 **(Impact factor 3.862)**
56. Mishra V[1], **Kesharwani P**[1,*]. Dendrimer technologies for brain tumor. Drug Discov Today. May 2016;21(5):766-78. **(Impact factor 7.851)**
57. Mansuri S, **Kesharwani P**, Jain K, Jain NK. Mucoadhesion: A promising approach in drug delivery system. Reactive and Functional Polymers 2016;100:151–72. **(Impact factor 3.975)**
58. Khan I, Gothwal A, Sharma AK, **Kesharwani P**, Gupta L, Iyer AK, Gupta U. PLGA nanoparticles and their versatile role in anticancer drug delivery. Crit Rev Ther Drug Carrier Syst. 2016;33(2):159-93. **(Impact factor 5.367)**
59. Dwivedi N, Shah J, Mishra V, Mohd Amin MCI, Iyer AK, **Kesharwani P***. Dendrimer mediated approaches for the treatment of brain tumor. J Biomater Sci Polym Ed. Feb 2016;27(7):557-80 **(Impact Factor 3.517).**

Year 2017:

60. **Kesharwani P*,** Gorain B, Low SY, Tan SA, Ling ECS, Lim YK, Chin CM, Lee PY, Lee CM, Ooi CH, Choudhury H, Pandey M. Nanotechnology based approaches for anti-diabetic drugs delivery. Diabetes Res Clin Pract. Feb 2018;136:52-77. **(Impact factor 5.602)**
61. Khurana RK, Beg S, Burrow AJ, Vashishta RK, Katare OP, Kaur S, **Kesharwani P**, Singh KK, Singh B. Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanomicellar systems. Eur J Pharm Biopharm. 2017 Dec;121:42-60. **(Impact factor 5.571)**
62. Cheriyan VT, Alsaab HO, Sekhar S, Stieber C, **Kesharwani P**, Sau S, Muthu M, Polin LA, Levi E, Iyer AK, Rishi AK. A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma. Oncotarget. Sep 2017;8:104928-104945. **(Impact factor 5.168)**
63. Jain A, Sharma G, Kushwah V, Garg NK, **Kesharwani P**, Ghoshal G, Singh B, Shivhare US, Jain S, Katare OP. Methotrexate and beta-carotene loaded-lipid polymer hybrid nanoparticles: a preclinical study for breast cancer. Nanomedicine (Lond). 2017 Aug;12(15):1851-1872. doi: 10.2217/nnm-2017-0011. Epub 2017 Jul 13. **(Impact factor 5.307)**
64. Luong D, Sau S, **Kesharwani P**, Iyer AK. Polyvalent folate-dendrimer-coated iron oxide theranostic nanoparticles for simultaneous magnetic resonance imaging and precise cancer cell targeting. Biomacromolecules. April 2017;18(4):1197-1209. **(Impact factor 6.998)**

65. Shringirishi M, Mahor A, Gupta R, Prajapati SK, Bansal K, **Kesharwani P***. Fabrication and characterization of nifedipine loaded β-cyclodextrin nanosponges: An in vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology. 2017;41:344-350. **(Impact factor 5)**
66. Madheswaran T, Baskaran R, Yoo BK, **Kesharwani P***. In vitro and in vivo skin distribution of 5α-reductase inhibitors loaded into liquid crystalline nanoparticles. J Pharm Sci. 2017 Nov;106(11):3385-3394. doi: 10.1016/j.xphs.2017.06.016 **(Impact factor 3.534)**
67. Luong D[1], **Kesharwani P[1]**, Alsaab HO, Sau S, Padhye S, Sarkar FH, Iyer AK. Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers. Colloids Surf B Biointerfaces. Sep 2017;157:490-502. **(Impact factor 5.8)**
68. Gawde KA, **Kesharwani P**, Sau S, Sarkar FH, Padhye S, Kashaw SK, Iyer AK. Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue. J Colloid Interface Sci. June 2017;496:290-299. **(Impact factor 8.128)**
69. Alsaab H, Alzhrani RM, **Kesharwani P**, Sau S, Boddu SH, Iyer AK. Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma. Pharmaceutics. 2017 Apr 18;9(2). pii: E15. doi: 10.3390/pharmaceutics9020015. **(Impact factor 6.321)**
70. Amjad MW[1], **Kesharwani P[1]**, Mohd Amin MCI, Iyer AK. Recent advances in the design, development, and targeting mechanisms of polymeric micelles for delivery of siRNA in cancer therapy. Progress in Polymer Science, January 2017;64:154–81. **(IMPACT FACTOR 29.190)**
71. Wickens JM, Alsaab HO, **Kesharwani P**, Bhise K, Amin MCIM, Tekade RK, Gupta U, Iyer AK. Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. Drug Discov Today. April 2017;22:665-680. **(Impact factor 7.851)**
72. Choudhury H, Gorain B, Pandey M, Chatterjee LA, Sengupta P, Das A, Molugulu N, **Kesharwani P***. Recent update on nanoemulgel as topical drug delivery system. J Pharm Sci. 2017 Jul;106(7):1736-1751. **(Impact factor 3.534)**
73. Gupta U, Kumar H, Mishra G, Kumar Sharma A, Gothwal A, **Kesharwani P**. Intranasal drug delivery: a non-invasive approach for the better delivery of neurotherapeutics. Pharm Nanotechnol. 2017;5(3):203-214. doi: 10.2174/2211738505666170515113936.
74. Md S, Haque S, Madheswaran T, Zeeshan F, Meka VS, Radhakrishnan AK, **Kesharwani P***. Lipid based nanocarriers system for topical delivery of photosensitizers. Drug Discovery Today, Volume 22, Issue 8, August 2017, Pages 1274-1283. doi: 10.1016/j.drudis.2017.04.010 **(Impact factor 7.851)**
75. Soni N, Tekade M, **Kesharwani P**, Bhattacharya P, Maheshwari R, Dua K, Hansbro PM, Tekade RK. Recent advances in oncological submissions of dendrimer. Curr Pharm Des. Aug 2017. doi: 10.2174/1381612823666170329150201. [Epub ahead of print]. **(Impact factor 3.116)**
76. Gorain B, Tekade M, **Kesharwani P**, Iyer AK, Kalia K, Tekade RK. The use of nanoscaffolds and dendrimers in tissue engineering. Drug Discov Today. 2017 Apr;22(4):652-664. doi: 10.1016/j.drudis.2016.12.007. Epub 2017 Feb 20. **(Impact factor 7.851)**
77. Meka VS, Sing MKG, Pichika MR, Nali SR, Kolapalli VRM, **Prashant Kesharwani***. A comprehensive review on polyelectrolyte complexes. Drug Discovery Today, Volume 22, Issue 11, November 2017, Pages 1697-1706. DOI 10.1016/j.drudis.2017.06.008 **(Impact factor 7.851)**
78. **Kesharwani P***, Gothwal A, Iyer AK, Jain K, Chourasia MK, Gupta U. Dendrimer nanohybrid carrier systems: An expanding horizon for targeted drug and gene delivery. Drug Discovery Today, Volume 23, Issue 2, February 2018, Pages 300-314 **(Impact factor 7.851)**
79. Hussain Z, Thu HE, Shuid AN, **Kesharwani P**, Khan S, Hussain F. Phytotherapeutic potential of natural herbal medicines for the treatment of mild-to-severe atopic dermatitis: A review of human clinical studies. Biomedicine & Pharmacotherapy, Sep 2017;93:596–608. **(Impact factor 6.529)**

80. Tatiparti K, Gawde KA, Alasab H, Sau S, Kashaw SK, Kesharwani P, Iyer AK. Pancreatic Cancer - The Role of Hypoxia. Journal of Pancreatic Cancer and Treatment, 2017, 1(1):1-5.
81. Choudhury H, Pandey M, Hua CK, Mun CS, Jing JK, Kong L, Ern LY, Ashraf NA, Kit SW, Yee TS, Pichika MR, Gorain B, **Kesharwani P***. An update on natural compounds in the remedy of diabetes mellitus: A systematic review. Journal of Traditional and Complementary Medicine, Volume 8, Issue 3, July 2018, Pages 361-376. DOI https://doi.org/10.1016/j.jtcme.2017.08.012 **(Impact factor 4.221)**
82. Jain A, Jain A, Parajuli P, Mishra V, Ghoshal G, Singh B, Shivhare US, Katare OP, **Kesharwani P***. Recent advances in galactose-engineered nanocarriers for the site-specific delivery of siRNA and anticancer drugs. Drug Discovery Today, Volume 23, Issue 5, May 2018, Pages 960-973 **(Impact factor 7.851)**
83. Thanikachalam PV, Ramamurthy S, Wong ZW, Koo BJ, Wong JY, Abdullah MF, Chin YH, Chia CH, Tan JY, Neo WT, Tan BS, Khan WF, **Kesharwani P***. Current attempts to implement microRNA-based diagnostics and therapy in cardiovascular and metabolic disease: a promising future. Drug Discovery Today, Volume 23, Issue 3, March 2018, Pages 460-480 **(Impact factor 7.851)**
84. Md S, Bhattmisra SK, Zeeshan F, Shahza N, Mujtaba MA, Meka VS, Radhakrishnan A, **Kesharwani P**, Baboot S, Ali J. Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. Journal of Drug Delivery Science and Technology. Feb 2018;43:295-310. **(Impact factor 5)**
85. Molugulu N, Yee LS, Ye YT, Khee TC, Nie LZ, Yee NJ, Yee TK, Liang TC, **Kesharwani P***. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. Diabetes Res Clin Pract. Oct 2017;132:157-168. **(Impact factor 5.602)**
86. Choudhury H, Gorain B, Pandey M, Kumbhar SA, Tekade RK, Iyer AK, **Kesharwani P***. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int J Pharm. Aug 2017;529(1-2):506-522. **(Impact factor 5.875)**
87. Khan I, Kumar H, Mishra G, Gothwal A, **Kesharwani P**, Gupta U. Polymeric nanocarriers: A new horizon for the effective management of breast cancer. Curr Pharm Des. Volume 23 , Issue 35 , 2017, Page: [5315 - 5326], DOI: 10.2174/1381612823666170829164828 **(Impact factor 3.116)**

Year 2018:

88. Khurana RK, Jain A, Jain A, Sharma T, Singh B, **Kesharwani P***. Administration of antioxidants in cancer: debate of the decade. Drug Discovery Today, Volume 23, Issue 4, April 2018, Pages 763-770 DOI https://doi.org/10.1016/j.drudis.2018.01.021**(Impact factor 7.851)**
89. Mishra V, Patil A, Thakur S, **Kesharwani P***. Carbon dots: emerging theranostic nanoarchitectures. Drug Discov Today. Volume 23, Issue 6, June 2018, Pages 1219-1232 **(Impact factor 7.851)**
90. Khurana RK, Kumar R, Gaspar BL, Welsby G, Welsby P, **Kesharwani P**, Katare OP, Singh KK, Singh B. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model. Materials Science and Engineering: C, Volume 91, 1 October 2018, Pages 645-658. https://doi.org/10.1016/j.msec.2018.05.010 **(Impact factor 7.328)**
91. Jain A, Sharma G, Ghoshal G, **Kesharwani P**, Singh B, Shivhare US, Katare OP. Lycopene loaded whey protein isolate nanoparticles: An innovative endeavor for enhanced bioavailability of lycopene and anti-cancer activity. International Journal of Pharmaceutics, Volume 546, Issues 1–2, 30 July 2018, Pages 97-105. https://doi.org/10.1016/j.msec.2018.05.010 **(Impact factor 5.875)**
92. Bapat RA, Chaubal TV, Joshi CP, Bapat PR, Choudhury H, Pandey M, Gorain B, **Kesharwani P***. An overview of application of silver nanoparticles for biomaterials in dentistry. Materials Science

and Engineering: C, Volume 91, 1 October 2018, Pages 881-898 DOI: https://doi.org/10.1016/j.msec.2018.05.069 **(Impact factor 7.328)**

93. Pandey M, Choudhury H, Yi CX, Mun CW, Ping GK, Rou GX, Singh BJKAAJ, Jhee ANA, Chin LK, **Kesharwani P**, Gorain B, Hussain Z. Recent updates on novel approaches in insulin drug delivery: A review of challenges and pharmaceutical implications. Curr Drug Targets. 2018 May 22. doi: 10.2174/1389450119666180523092100. [Epub ahead of print] **(Impact factor 3.465)**
94. Singh G, **Kesharwani P***, Srivastava AK. Tuberculosis Treated by Multiple Drugs: An Overview. Curr Drug Deliv. 2018;15(3):312-320. **(Impact factor 2.565)**
95. Pandey M, Choudhury H, Yeun OC, Yin HM, Lynn TW, Tine CLY, Wi NS, Yen KCC, Phing CS, **Kesharwani P**, Bhattamisra SK, Gorain B. Perspectives of nanoemulsion strategies in the improvement of oral, parenteral and transdermal chemotherapy. Curr Pharm Biotechnol. 2018 Jun 5. doi: 10.2174/1389201019666180605125234. [Epub ahead of print] **(Impact factor 2.459)**
96. Choudhury H, Pandey M, Chin PX, Phang YL, Cheah JY, Ooi SC, Mak KK, Pichika MR, **Kesharwani P**, Hussain Z, Gorain B. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Res. 2018 Oct;8(5):1545-1563. doi: 10.1007/s13346-018-0552-2. [Epub ahead of print] **(Impact factor 4.615)**
97. Gorain B, Choudhury H, Pandey M, **Kesharwani P**. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy. Mater Sci Eng C Mater Biol Appl. Oct 2018;91:868-880. **(Impact factor 7.328)**
98. Mishra V, Thakur S, **Kesharwani P**, Gupta P, Vyas M. Precision medicine in cancer treatment: An update. Asian Journal of Pharmaceutics • Jan-Mar 2018 (Suppl) • 12 (1) | S9-S12.
99. Gorain B, Choudhury H, Pandey M, **Kesharwani P**. Mechanistic description of natural herbs in the treatment of dementia: A systematic review. Current Psychopharmacology, Volume 7, Number 2, 2018, pp. 149-164(16) DOI: 10.2174/2211556007666180420124544 **(Impact factor 0.149)**
100. Mak KK, Pichika MR, Ling LR, Sern JCC, Yang SC, Ying TW, Yin HM, Dione MS, Hui OK, Chyi ALY, Balijepalli MK, **Kesharwani P***. Comparison of cisplatin monotherapy and cisplatin-containing combination therapy in term of survival rate in recurrent cervical cancer. Acta Scientific Pharmaceutical Sciences. 2018;2:3:22-28.
101. Nallamolu S, Jayanti VR, Chitneni M, **Kesharwani P***. Solubility enhancement of poorly water-soluble drug aprepitant for oral delivery by self-micro emulsifying drug. Acta Scientific Pharmaceutical Sciences. 2018;2:3:2-13.
102. Bapat RA, Joshi CP, Bapat P, Chaubal TV, Pandurangappa R, Jnanendrappa N, Gorain B, Khurana S, Kesharwani P*. The use of nanoparticles as biomaterials in dentistry. Drug Discovery Today, Volume 24, Issue 1, January 2019, Pages 85-98 Drug Discov Today. 2018. doi: 10.1016/j.drudis.2018.08.012. [Epub ahead of print] **(Impact factor 7.851)**
103. Meher JG, Dixit S, Pathan DK, Singh Y, Chandasana H, Pawar VK, Sharma M, Bhatta RS, Konwar R, **Kesharwani P**, Chourasia MK. Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S344-S358. DOI: ps://doi.org/10.1080/21691401.2018.1492933 **(Impact factor 5.678)**
104. Gorain B, Choudhury H, Pandey M, **Kesharwani P**, Abeer MM, Tekade RK, Hussain Z. Carbon nanotube scaffolds as emerging nanoplatform for myocardial tissue regeneration: A review of recent developments and therapeutic implications. Biomedicine & Pharmacotherapy Aug 2018;104:496-508. **(Impact factor 6.529)**

105. Mishra V, Kesharwani P, Jain NK. Biomedical applications and toxicological aspects of functionalized carbon nanotubes. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2018;35:4:293-330. **(Impact factor 4.889)**
106. Tambuwala MM, Kesharwani P, Shukla R, Thompson PD, McCarron PA. Caffeic acid phenethyl ester (CAPE) reverses fibrosis caused by chronic colon inflammation in murine model of colitis. Pathol Res Pract. 2018 Nov;214(11):1909-1911 **(Impact Factor: 3.250)**.

Year 2019:

107. **Kesharwani P***, Choudhury H, Meher JG, Pandey M, Gorain B. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Progress in Materials Science, June 2019:103:484-508 **(IMPACT FACTOR: 48.580)**.
108. Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, **Kesharwani P***. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discovery Today, Volume 25, Issue 1, January 2020, Pages 223-229. doi: 10.1016/j.drudis.2019.11.003. [Epub ahead of print] **(Impact factor 7.851)**.
109. Choudhury H, Pandey M, Yin TH, Kaur T, Jia GW, Tan SQL, Weijie H, Yang EKS, Keat CG, Bhattamishra SK, **Kesharwani P**, Md S, Molugulu N, Pichika MR, Gorain B. Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology. Mater Sci Eng C Mater Biol Appl. Aug 2019;101:596-613. **(Impact factor 7.328)**
110. Choudhury H, Gorain B, Pandey M, Kaur R, **Kesharwani P***. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int J Pharm. June 2019;565:509-522 **(Impact factor 5.875)**.
111. Dwivedi N, Shaha J, Mishra V, Tambuwala M, **Kesharwani P***. Nanoneuromedicine for management of neurodegenerative disorder. Journal of Drug Delivery Science and Technology. Feb 2019;49:477-490 **(Impact Factor: 5)**.
112. Pandey D, **Kesharwani P***, Jain D. Entrapment of drug-sorbate complex in submicron emulsion: A potential approach to improve antimicrobial activity in bacterial corneal infection. Journal of Drug Delivery Science and Technology 2019;49:February 2019:455-462. **(Impact Factor: 5)**.
113. Zeeshan, F., Tabbassum, M. &**Kesharwani, P***. Investigation on secondary structure alterations of protein drugs as an indicator of their biological activity upon thermal exposure. Protein J. 2019 Oct;38(5):551-564. doi: 10.1007/s10930-019-09837-4. **(Impact factor 2.371)**
114. Bapat RA, Dharmadhikari S, Chaubal TV, Amin MCIM, Bapat P, Gorain B, Choudhury H, Vincent C, **Kesharwani P***. The potential of dendrimer in delivery of therapeutics for dentistry. Heliyon. Oct 2019;5(10):e02544.
115. Tripathi PK, Gorain B, Choudhury H, Srivastava A, **Kesharwani P***. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon 4 (March 2019) e01343. https://doi.org/10.1016/j.
116. Bakshi HA, Mishra V, Satija S, Mehta M, Hakkim FL, **Kesharwani P**, Dua K, Chellappan DK, Charbe NB, Shrivastava G, Rajeshkumar S, Aljabali AA, Al-Trad B, Pabreja K, Tambuwala MM. Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis. Inflammation. Dec 2019;42(6):2032-2036. doi: 10.1007/s10753-019-01065-3 **(Impact Factor: 4.092)**.
117. Choudhury H, Zakaria NFB, Tilang PAB, Tzeyung AS, Pandey M, Chatterjee B, Alhakamy NA, Bhattamishra SK, **Kesharwani P,** Gorain B, Md S. Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery. Journal of Drug Delivery Science and Technology. Dec 2019;54:101301 **(Impact Factor: 5)**.

Year 2020:

118. G.S. Bhagwat, R.B. Athawale, R.P. Gude, S. Md, N.A. Alhakamy, U.A. Fahmy, **P. Kesharwani***, Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy, Front. Pharmacol. 11 (2020). https://doi.org/10.3389/fphar.2020.614290. **(Impact factor 5.810)**
119. P. Rathore, A. Mahor, S Jain, A. Haque, **P. Kesharwani***. Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin. RSC Adv., 2020, 10, 43629-43639. DOI: 10.1039/D0RA07640F **(Impact factor 3.361)**
120. Gorain B, Choudhury H, Molugulu N, Athawale RB, **Kesharwani P***. (2020) Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global Economy. Front. Public Health 8:606129. doi: 10.3389/fpubh.2020.606129 **(Impact factor 5.810)**
121. Maddiboyina, B.; Hanumanaik, M.; Nakkala, R. K.; Jhawat, V.; Rawat, P.; Alam, A.; Foudah, A. I.; Alrobaian, M. M.; Shukla, R.; Singh, S.; **Kesharwani, P***. Formulation and Evaluation of Gastro-Retentive Floating Bilayer Tablet for the Treatment of Hypertension. Heliyon 2020, 6 (11), e05459. https://doi.org/10.1016/j.heliyon.2020.e05459.
122. Agrawal, M.; Saraf, S.; Saraf, S.; Murty, U. S.; Kurundkar, S. B.; Roy, D.; Joshi, P.; Sable, D.; Choudhary, Y. K.; **Kesharwani, P***.; et al. In-Line Treatments and Clinical Initiatives to Fight against COVID-19 Outbreak. Respir. Med. 2020, 106192. https://doi.org/10.1016/j.rmed.2020.106192. **(Impact factor 3.095)**
123. Sood, S.; Maddiboyina, B.; Rawat, P.; Garg, A. K.; Foudah, A. I.; Alam, A.; Aldawsari, H. M.; Riadi, Y.; Singh, S.; **Kesharwani, P***. Enhancing the Solubility of Nitazoxanide with Solid Dispersions Technique: Formulation, Evaluation, and Cytotoxicity Study. J. Biomater. Sci. Polym. Ed. 2021 Mar;32(4):477-487 https://doi.org/10.1080/09205063.2020.1844506. **(Impact factor 3.517)**
124. Krishna KV, Dubey SK, Singhvi G, **Kesharwani P***. MAPK Pathway: Potential role in Glioblastoma Multiforme, Interdisciplinary Neurosurgery, Volume 23, March 2021, 100901 https://doi.org/10.1016/j.inat.2020.100901.
125. Hejmady S, Pradhan R, Alexander A, Agrawal M, Singhvi G, Gorain B, Tiwari S, **Kesharwani P***, Dubey SK. Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discovery Today, Volume 25, Issue 12, December 2020, Pages 2227-2244. https://doi.org/10.1016/j.drudis.2020.09.031 **(Impact factor 7.851)**
126. Singh PK, Gorain B, Choudhury H, Singh SK, Whadwa P, Sahu SS, Gulati M, **Kesharwani P***. Macrophage targeted amphotericin B nanodelivery systems against visceral leishmaniasis, Materials Science and Engineering: B, Volume 258, August 2020, 114571 https://doi.org/10.1016/j.mseb.2020.114571. **(Impact factor 4.051)**
127. Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Gupta U, **Kesharwani P**, Ravichandiran V, Kumar P, Naidu VGM, Murty US, Ajazuddin A, Alexander A. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery, J. Control. Release. 327 (2020) 235–265. https://doi.org/10.1016/j.jconrel.2020.07.044. **(Impact factor 10.8)**
128. Nallamolu S, Jayanti VR, Chitneni M, Khoon LY, **Kesharwani P***. Self-micro Emulsifying Drug Delivery System "SMEDDS" for Efficient Oral Delivery of Andrographolide, Drug Deliv. Lett. 10 (July 2019) 38–53. https://doi.org/10.2174/2210303109666190723145209.
129. Bapat RA, Chaubal TV, Dharmadhikari S, Abdulla AM, Bapat P, Alexander A, Dubey SK, **Kesharwani P***. Recent advances of gold nanoparticles as biomaterial in dentistry. Int J Pharm. Aug 2020;586:119596 https://doi.org/10.1016/j.ijpharm.2020.119596 **(Impact factor 5.875)**
130. Singh S, Alrobaian MM, Molugulu N, Agrawal N, Numan A, **Kesharwani P***. Pyramid-shaped PEG-PCL-PEG polymeric-based model systems for site-specific drug delivery of vancomycin with

enhance antibacterial efficacy. ACS Omega, May 2020, 5, 21, 11935–11945 https://doi.org/10.1021/acsomega.9b04064 **(Impact factor 3.521)**

131. Gorain B, Choudhury H, Nair AB, Dubey SK, Kesharwani P*. Theranostic application of nanoemulsion in chemotherapy. Drug Discovery Today, Volume 25, Issue 7, July 2020, Pages 1174-1188 DOI: https://doi.org/10.1016/j.drudis.2020.04.013 **(Impact factor 7.851)**
132. Singh S, Numan A, Agrawal N, Tambuwala MW, Singh V, **Kesharwani P***. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. International Immunopharmacology June 2020;83:106417 https://doi.org/10.1016/j.intimp.2020.106417 **(Impact factor 4.932)**
133. Choudhury H, Pandey M, Qing Y, Che L, Low Y, Lee CT, Cheng Marilyn TCL, Loh HS, Lim YP, Lee CF, Bhattamishra SK, Kesharwani P, Gorain B. Silver nanoparticles: Advanced and promising technology in diabetic wound therapy. Materials Science and Engineering: C 2020;112:110925 https://doi.org/10.1016/j.msec.2020.110925 **(Impact factor 7.328)**
134. Gorain B, Rajeswary DC, Pandey M, **Kesharwani P**, Kumbhar SA, Choudhury H. Nose to brain delivery of nanocarriers towards attenuation of demented condition. Current Pharmaceutical Design. DOI: https://doi.org/10.2174/1381612826666200313125613**(Impact Factor: 3.116)**
135. Sivaram N, Jayanti VR, Chitneni M, Khoon LY, **Kesharwani P***. Self-microemulsifying drug delivery system (SMEDDS) for a novel medicative compound against depression: a preparation and bioavailability study in rats. Drug Delivery Letters 2020;10:38-53.
136. Tagde P, Kulkarni GT, Mishra DK, **Kesharwani P***. Recent advances in folic acid engineered nanocarriers for treatment of breast cancer. Journal of Drug Delivery Science and Technology 2020;56:101613. **(Impact Factor: 5)**
137. Verma LT, Singh N, Gorain B, Choudhury H, Tambuwala MM, **Kesharwani P***, Shukla R. Recent Advances in Self-Assembled Nanoparticles for Drug Delivery. Curr Drug Deliv. 2020;17(4):279-291. doi: 10.2174/1567201817666200210122340. **(Impact Factor: 2.565)**
138. Devi L, Gupta R, Jain SK, Singh S, **Kesharwani P***. Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of Gemcitabine with natural polysaccharides for treatment of breast cancer. Journal of Drug Delivery Science and Technology, April 2020;56:101565. **(Impact Factor: 5)**
139. Tripathi PK, Gupta S, Rai S, Shrivatava A, Tripathi S, Singh S, Khopade AJ, **Kesharwani P***. Curcumin loaded poly (amidoamine) dendrimer-plamitic acid core-shell nanoparticles as anti-stress therapeutics. Drug Dev Ind Pharm. March 2020;46(3):412-426 **(Impact Factor: 3.232).**
140. Aljabali AAA, Bakshi HA, Hakkim FL, Haggag YA, **Kesharwani P**, Tambuwala MM. Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α. Cancers (Basel). 2020 Jan 1;12(1). pii: E113. doi: 10.3390/cancers12010113. **(Impact Factor: 6.639)**
141. Shrivastava G, Bakshi HA, Aljabali AA, Mishra V, Faruck LH, Charbe NB, **Kesharwani P**, Chellappan DK, Dua K, Tambuwala MM. Nucleic acid aptamers as potential Nucleus targeted drug delivery system. Curr Drug Deliv. 2020;17(2):101-111. doi: 10.2174/1567201817666200106104332. [Epub ahead of print] **(Impact Factor: 2.565)**

Year 2021:

142. D Singh, **P. Kesharwani***, NA Alhakamy, HR, Siddique. Accentuating CircRNA-miRNA-Transcription Factors Axis: A Conundrum in Cancer Research. Front. Pharmacol. (Januray 2022) 12:784801. doi: 10.3389/fphar.2021.784801 **(Impact factor 5.810)**
143. R. Kumar Bandaru, S.R. Rout, G. Kenguva, B. Gorain, N.A. Alhakamy, **P. Kesharwani***, R. Dandela, Recent Advances in Pharmaceutical Cocrystals: From Bench to Market, Front. Pharmacol. 12 (Nov 2021). https://doi.org/10.3389/FPHAR.2021.780582. **(Impact factor: 5.810)**

144. S. Gorantla, G. Wadhwa, S. Jain, S. Sankar, K. Nuwal, A. Mahmood, S.K. Dubey, R. Taliyan, **P. Kesharwani***, G. Singhvi, Recent advances in nanocarriers for nutrient delivery, Drug Deliv. Transl. Res. (Nov 2021). https://doi.org/10.1007/S13346-021-01097-Z. (Impact factor: 4.617)
145. S. Mule, A. Singh, K. Greish, A. Sahebkar, **P. Kesharwani***, R. Shukla, Drug repurposing strategies and key challenges for COVID-19 management, J. Drug Target. 0 (December 2021) 1–17. https://doi.org/10.1080/1061186x.2021.2013852. (Impact factor: 5.121)
146. N. Shakour, F. Hadizadeh, **P. Kesharwani**, A. Sahebkar, 3D-QSAR Studies of 1,2,4-Oxadiazole Derivatives as Sortase A Inhibitors, Biomed Res. Int. 2021 (December 2021) 1–10. https://doi.org/10.1155/2021/6380336. (Impact factor: 3.411)
147. Ataei M, Roufogalis BD, **Kesharwani P**, Jamialahmadi T, Sahebkar A. Harnessing Therapeutic Potentials of Statins Using Nanofibrous Carriers. Bioinorganic Chemistry and Applications, Bioinorganic Chemistry and Applications, (November 2021). https://doi.org/10.1155/2021/7265505 (Impact factor: 8.110)
148. Sheikh A, Md S, **Kesharwani, P***. RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy. J. Control. Release (December 2021);340:221–242. https://doi.org/10.1016/J.JCONREL.2021.10.028 (Impact factor: 10.8)
149. A. Singh, S.K. Maharana, R. Shukla, **P. Kesharwani***, Nanotherapeutics approaches for targeting alpha synuclien protein in the management of Parkinson disease, Process Biochem. 110 (November 2021) 181–194. https://doi.org/10.1016/J.PROCBIO.2021.08.008. (Impact factor: 3.757)
150. Rai RH, Popli H, Ganguly P, **Kesharwani P**. Technology Enabled Teaching and Online Learning in North India during Lockdown in Pandemic COVID 19. International Journal of Science and Research (IJSR), (June 2021), Volume 10 Issue 6, June 2021, 84 -87.
151. Y. Nitheesh, R. Pradhan, S. Hejmady, R. Taliyan, G. Singhvi, A. Alexander, **P. Kesharwani***, S.K. Dubey, Surface engineered nanocarriers for the management of breast cancer, Mater. Sci. Eng. C. 130 (November 2021) 112441. https://doi.org/10.1016/J.MSEC.2021.112441. (Impact factor: 7.328)
152. Gorain B, Al-Dhubiab BE, Nair A, **Kesharwani P**, Pandey M, Choudhury H. Multivesicular liposome: A lipid-based drug delivery system for efficient drug delivery, Curr. Pharm. Des. 27 (December 2021). https://doi.org/10.2174/1381612827666210830095941. (Impact factor: 3.309)
153. Gyanewali S, **Kesharwani P***, Sheikh A, Ahmad FJ, Trivedi R, Talegaonkar S. Formulation development and in vitro–in vivo assessment of protransfersomal gel of anti-resorptive drug in osteoporosis treatment. International Journal of Pharmaceutics, (October 2021);608:121060. (Impact factor: 5.875)
154. Singh V, **Kesharwani P***. Recent advances in microneedles-based drug delivery device in the diagnosis and treatment of cancer. Journal of Controlled Release. (September 2021);338:394-409 (Impact factor: 10.8)
155. Shaikh A, **Kesharwani P***. An insight into aptamer engineered dendrimer for cancer therapy. Eur Polym J, (October 2021), volume 159, 110746 (Impact factor: 6)
156. Singh S, Numan A, Somaily HH, Gorain B, Ranjan S, Rilla K, Siddique HR, **Kesharwani P***. Nano-enabled strategies to combat methicillin-resistant Staphylococcus aureus. Materials Science and Engineering: C, Volume 129, (October 2021), 112384 (Impact factor: 7.328)
157. Singh A, Handa M, Ruwali M, Flora SJ., Shukla R, **Kesharwani P***. Nanocarrier mediated autophagy: An emerging trend for cancer therapy. Process Biochem (July 2021);109:198–206. https://doi.org/10.1016/J.PROCBIO.2021.07.011. (Impact factor: 3.757)
158. Srivastava S, Mahor A, Singh G, Bansal K, Singh PP, Gupta R, **Kesharwani P***. Formulation development, in vitro and in vivo evaluation of topical hydrogel formulation of econazole nitrate-loaded β-cyclodextrin nanosponges. Journal of Pharmaceutical Sciences, Volume 110, Issue 11, (November 2021), Pages 3702-3714 (Impact factor: 3.534)

159. Singh V, Sahebkar A, **Kesharwani P***. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery. Eur Polym J. (September 2021);158:110683. https://doi.org/10.1016/J.EURPOLYMJ.2021.110683. (Impact factor: 6)
160. Kaur H, **Kesharwani P***. Advanced nanomedicine approaches applied for treatment of skin carcinoma. J Control Release (September 2021) ;337:589–611. https://doi.org/10.1016/J.JCONREL.2021.08.003. (Impact factor: 10.8)
161. Gaurav, Hasan N, Malik AK, Singh V, Raza K, Ahmad FJ, **Kesharwani P***. Recent update of 3D printing technology in pharmaceutical formulation development. Journal of Biomaterials Science, Polymer Edition, (August 2021) ;32(17)2306-2330 (Impact factor: 3.517)
162. Chadar R, Afzal O, Alqahtani SM, **Kesharwani P***. Carbon nanotubes as an emerging nanocarrier for the delivery of doxorubicin for improved chemotherapy. Colloids Surfaces B Biointerfaces (Dec ember 2021);208:112044. https://doi.org/10.1016/J.COLSURFB.2021.112044. (Impact factor: 5.8)
163. Mishra P, Handa M, Ujjwal RR, Singh V, **Kesharwani P***, Shukla R. Potential of nanoparticulate based delivery systems for effective management of alopecia. Colloids Surfaces B Biointerfaces (December 2021); 208:112050. https://doi.org/10.1016/J.COLSURFB.2021.112050. (Impact factor: 5.8)
164. Paul RK, **Kesharwani P***, Raza K. Recent update on nano-phytopharmaceuticals in the management of diabetes. Journal of Biomaterials Science, Polymer Edition, (July 2021);1–28. https://doi.org/10.1080/09205063.2021.1952381 (Impact factor: 3.517)
165. Singh A, Mallika TN, Gorain B, Yadav AK, Tiwari S, Flora SJS, Shukla R, **Kesharwani P***. Quantum dot: Heralding a brighter future in neurodegenerative disorders. Journal of Drug Delivery Science and Technology, (October 2021);65, 102700. https://doi.org/10.1016/J.JDDST.2021.102700 (Impact factor: 5)
166. Srivastava V, Singh A, Jain GK, Ahmad FJ, Shukla R, **Kesharwani P***. Viral vectors as a promising nanotherapeutic approach against neurodegenerative disorders. Process Biochemistry, (October 2021);109, 130–142. https://doi.org/10.1016/J.PROCBIO.2021.07.002 (Impact factor: 3.757)
167. Kumar AVP, Dubey SK, Tiwari S, Puri A, Hejmady S, Gorain B, Kesharwani P. Recent advances in nanoparticles mediated photothermal therapy induced tumor regression. International Journal of Pharmaceutics, (September 2021);120848. https://doi.org/10.1016/J.IJPHARM.2021.120848 (Impact factor: 5.875)
168. Chadar R, Afsana, **Kesharwani P***. Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer. International Journal of Pharmaceutics (August 2021):605;120835 doi.org/10.1016/j.ijpharm.2021.120835 (Impact factor: 5.875)
169. Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, Kesharwani P*, Rajak H. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. (December 2021);73(6):1539-1550. (Impact factor: 3.024)
170. Singh V, **Kesharwani P***. Dendrimer as a promising nanocarrier for the delivery of doxorubicin as an anticancer therapeutics. J Biomater Sci Polym Ed. (October 2021);32(14):1882-1909. Journal of Biomaterials Science, Polymer Edition 2021, doi.org/10.1080/09205063.2021.1938859 (Impact factor: 3.517).
171. Dubey SK, Kali M, Hejmady S, Saha RN, Alexander A, **Kesharwani P***. Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer. European Journal of Pharmaceutical Sciences, (September 2021); 164:105890 (Impact factor: 6).
172. Modi D, Warsi MMH, Garg V, Bhatia M, **Kesharwani P***, Jain GK. Formulation development, optimization, and in vitro assessment of thermoresponsive ophthalmic pluronic F127-chitosan in situ

tacrolimus gel. J Biomater Sci Polym Ed. (September 2021);32(13):1678-1702 (Impact factor: 3.517).

173. Zeeshan F, Madheswaran T, Panneerselvam J, Taliyan R, **Kesharwani P***. Human serum albumin as multifunctional nanocarrier for cancer therapy. Journal of Pharmaceutical Sciences. Volume 110, Issue 9, (September 2021), Pages 3111-3117 (Impact factor: 3.534).
174. Surekha B, Komman NS, Dubey SK, Kumar AVP, Shukla R, **Kesharwani P***. PAMAM dendrimer as a talented multifunctional biomimetic nanocarrier for cancer diagnosis and therapy. Colloids and Surfaces B: Biointerfaces (August 2021); 204: 111837 (Impact factor: 5.8).
175. Shukla R, Singh A, Handa M, Flora SJS, **Kesharwani P***. Nanotechnological approaches for targeting amyloid-β aggregation with potential for neurodegenerative disease therapy and diagnosis. Drug Discovery Today, Volume 26, Issue 8, (August 2021), Pages 1972-1979 **(Impact factor 7.851)**
176. Bapat RA, Parolia A, Chaubal T, Dharamadhikari S, Abdulla AM, Sakkir N, Arora S, Bapat P, Sindi AM, **Kesharwani P***. Recent update on potential cytotoxicity, biocompatibility and preventive measures of biomaterials used in dentistry. Biomater. Sci., 2021,9:3244-3283 (April 2021). https://doi.org/10.1039/D1BM00233C **(Impact factor 6.183)**
177. Agrawal M, Prathyusha E, Ahmed H, Dubey SK, **Kesharwani P**, Singhvi G, Naidu VGM, Alexander A. Biomaterials in treatment of Alzheimer's disease. Neurochemistry International, (May 2021); 145:105008 **(Impact factor 3.881)**.
178. Kakoty V, Sarathlal KC, Dubey SK, Yang CH, **Kesharwani P***, Taliyan R. The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. Neuroscience Letters (May 2021); 753:135865 **(Impact factor 2.274)**.
179. Dubey SK, Pradhan R, Hejmady S, Singhvi G, Choudhury H, Gorain B, **Kesharwani P***. Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift. International Journal of Pharmaceutics, (May 2021); 600:120499 **(Impact factor 5.875)**.
180. Singh AR, Desu PK, Nakkala RK, Kondi V, Devi S, Alam MS, Hamid H, Athawale RB, **Kesharwani P***. Nanotechnology-based approaches applied to nutraceuticals. Drug Deliv. and Transl. Res. 2022 Mar;12(3):485-499. doi: 10.1007/s13346-021-00960-3 **(Impact factor 5.671)**.
181. Singh S, Numan A, Maddiboyina B, Arora S, Riadi Y, Md S, Alhakamy NA, **Kesharwani P***. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Drug Discov Today, (July 2021); 26(7):1721-1727 **(Impact factor 7.851)**.
182. Garg AK, Maddiboyina B, Alqarni MHS, Alam A, Aldawsari HM, Rawat P, Singh S, **Kesharwani P***. Solubility enhancement, formulation development and antifungal activity of luliconazole niosomal gel-based system, J Biomater Sci Polym Ed, (June 2021); 32(8):1009-1023 **(Impact factor 3.517)**.
183. Hasan N, Imran M, **Kesharwani P**, Khanna K, Karwasra R, Sharma N, Rawat S, Sharma D, Ahmad FJ, Jain GK, Bhatnagar A, Talegaonkar S. Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Int J Pharm. (April 2021);120428. doi: 10.1016/j.ijpharm.2021.120428. **(Impact factor 5.875)**
184. Patnaik S, Gorain B, Padhi S, Choudhury H, Gabr GA, Md S, Mishra DK, **Kesharwani P*.** Recent update of toxicity aspects of nanoparticulate systems for drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, Volume 161, (April 2021), Pages 100-119 **(Impact factor 4.604)**
185. Kakoty V, Sarathlal KC, Dubey SK, Yang CH, Kesharwani P*, Taliyan R. Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease. Neuroscience Letters. Volume 750, 17 (April 2021), 135769 **(Impact factor 2.274)**

186. Choudhari M, Hejmady S, Saha RN, Damle S, Singhvi G, Alexander A, **Kesharwani P*,** Dubey SK. Evolving New-Age Strategies to Transport Therapeutics Across the Blood-Brain-Barrier. International Journal of Pharmaceutics, Volume 599, 15 April 2021, 120351 **(Impact factor 5.875)**
187. Nallamolu S, Jayanti VR, Chitneni M, Khoon LY, Sood S, Riadi Y, Kesharwani P*. Fabrication of thermodynamically stable self-microemulsifying drug delivery system of resveratrol with enhanced solubility and chemical stability. (February 2021) Journal of Dispersion Sciences and Technology https://doi.org/10.1080/01932691.2021.1880432**(Impact factor 2.057)**
188. Gupta A, Mathur R, Singh S, Bag N, Khan UA, Ahmad FJ, Gabr GA, Kesharwani P*, Jain GK. ^{99}mTc-Methionine Gold Nanoparticles as a Promising Biomaterial for Enhanced Tumor Imaging. Journal of Pharmaceutical Sciences 2021, Volume 110,Issue 2, (February 2021), Pages 888-897**(Impact factor 3.534)**
189. Garg, V.; Nirmal, J.; Riadi, Y.; **Kesharwani, P***.; Kohli, K.; Jain, G. K. Amelioration of Endotoxin-Induced Uveitis in Rabbit by Topical Administration of Tacrolimus Proglycosome Nano-Vesicles. J. Pharm. Sci. (February 2021), 110 (2), 871–875. https://doi.org/10.1016/j.xphs.2020.10.060. **(Impact factor 3.534)**
190. Shah, R.; Soni, T.; Shah, U.; Suhagia, B. N.; Patel, M. N.; Patel, T.; Gabr, G. A.; Gorain, B.; **Kesharwani, P***. Formulation Development and Characterization of Lumefantrine Nanosuspension for Enhanced Antimalarial Activity. J Biomater Sci Polym Ed. (May 2021) ;32(7):833-857 **(Impact factor 3.517)**
191. Paroha, S.; Verma, J.; Dubey, R. D.; Dewangan, R. P.; Molugulu, N.; Bapat, R. A.; Sahoo, P. K.; **Kesharwani, P***. Recent Advances and Prospects in Gemcitabine Drug Delivery Systems. International Journal of Pharmaceutics. Elsevier B.V. (January 2021), p 120043. https://doi.org/10.1016/j.ijpharm.2020.120043. **(Impact factor 5.875)**
192. Dubey, S. K.; Parab, S.; Dabholkar, N.; Agrawal, M.; Singhvi, G.; Alexander, A.; Bapat, R. A.; **Kesharwani, P***. Oral Peptide Delivery: Challenges and the Way Ahead. Drug Discovery Today, Volume 26, Issue 4, (April 2021), Pages 931-950. https://doi.org/10.1016/j.drudis.2021.01.001. **(Impact Factor 7.851)**
193. **Kesharwani, P.***; Md, S.; Alhakamy, N. A.; Hosny, K. M.; Haque, A. QbD Enabled Azacitidine Loaded Liposomal Nanoformulation and Its In Vitro Evaluation. Polymers (Basel). (January 2021), 13 (2), 250. https://doi.org/10.3390/polym13020250. **(Impact factor 4.329)**

Year 2022:

194. M. Imran, S.P. Patil, M.A.S. Abourehab, V. Aeri, P. Kesharwani, Quality by design-based optimization of Soxhlet extraction and identification of ephedrine by a HPTLC method for Sida rhombifolia and Sida Cordifolia, Biomed. Chromatogr. (August 2022) e5479. https://doi.org/10.1002/BMC.5479. **(Impact factor: 1.911)**
195. U. Rehman, N. Parveen, A. Sheikh, M.A.S. Abourehab, A. Sahebkar, P. Kesharwani, Polymeric nanoparticles-siRNA as an emerging nano-polyplexes against ovarian cancer, Colloids Surfaces B Biointerfaces. 218 (August 2022) 112766. https://doi.org/10.1016/J.COLSURFB.2022.112766. **(Impact factor: 5.8)**
196. F. Mohammadpour, H. Kamali, L. Gholami, A.P. McCloskey, P. Kesharwani, A. Sahebkar, Solid lipid nanoparticles: a promising tool for insulin delivery, Expert Opinion on Drug Delivery (November 2022). https://doi.org/10.1080/17425247.2022.2138328. **(Impact factor: 8.129)**
197. A. Mahdavi Gorabi, M. Sadat Ravari, M.J. Sanaei, S. Davaran, P. Kesharwani, A. Sahebkar, Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles, Int. Immunopharmacol. 113 (December 2022) 109300. https://doi.org/10.1016/J.INTIMP.2022.109300. **(Impact factor: 5.714)**

198. M. Hatamipour, F. Hadizadeh, M.R. Jaafari, Z. Khashyarmanesh, P. Kesharwani, A.P. McCloskey, A. Sahebkar, Formulation development and in vitro–in vivo anticancer potential of novel nanoliposomal fluorinated curcuminoids, Process Biochem. 122 (November 2022) 250–257. https://doi.org/10.1016/J.PROCBIO.2022.09.001. **(Impact factor: 4.885)**
199. A. Arab, A.R. Nikpoor, P. Asadi, R. Iraei, R. Yazdian-Robati, A. Sheikh, P. Kesharwani, Virus-Like Nanoparticles (VLPs) based technology in the development of breast cancer vaccines, Process Biochem. (October 2022). https://doi.org/10.1016/J.PROCBIO.2022.10.020. **(Impact factor: 4.885)**
200. V. Arora, M.A.S. Abourehab, G. Modi, P. Kesharwani, Dendrimers as prospective nanocarrier for targeted delivery against lung cancer, Eur. Polym. J. 180 (October 2022) 111635. https://doi.org/10.1016/J.EURPOLYMJ.2022.111635. **(Impact factor: 6)**
201. S.M. Arabi, H. Bahari, S. Hamidipor, L.S. Bahrami, Z. Feizy, M. Nematy, P. Kesharwani, A. Sahebkar, The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis, Phyther. Res. (October 2022). https://doi.org/10.1002/PTR.7642. **(Impact factor: 6.388)**
202. A. Sheikh, M.A.S. Abourehab, P. Kesharwani, The clinical significance of 4D printing, Drug Discov. Today. 28 (October 2022) 103391. https://doi.org/10.1016/J.DRUDIS.2022.103391. **(Impact factor: 5.546)**
203. G. Arora, A. Mishra, Gaurav, N. Chandra, P. Kesharwani, G.K. Jain, In Vitro and In Vivo Scalp Retention and Penetration of 99mTc-Minoxidil Solution, J. Pharm. Sci. (September 2022). https://doi.org/10.1016/J.XPHS.2022.09.016. **(Impact factor: 3.784)**
204. Z. Khan, M.A.S. Abourehab, N. Parveen, K. Kohli, P. Kesharwani, Recent advances in microbeads-based drug delivery system for achieving controlled drug release, (September 2022) volume 34, 2023;541-564. https://doi.org/10.1080/09205063.2022.2127237. Journal of Biomaterials Science, Polymer Edition **(Impact factor: 3.682)**
205. H. Choudhury, M. Pandey, R. Mohgan, J.S.J. Jong, R.N. David, W.Y. Ngan, T.L. Chin, S. Ting, P. Kesharwani, B. Gorain, Dendrimer-based delivery of macromolecules for the treatment of brain tumor, Biomater. Adv. 141 (September 2022) 213118. https://doi.org/10.1016/J.BIOADV.2022.213118. **(Impact factor: 7.546)**
206. M. Fatima, M.A.S. Abourehab, G. Aggarwal, G.K. Jain, A. Sahebkar, P. Kesharwani, Advancement of cell-penetrating peptides in combating triple-negative breast cancer, Drug Discov. Today. 27 (September 2022) 103353. https://doi.org/10.1016/J.DRUDIS.2022.103353. **(Impact factor: 8.369)**
207. A. Aziz, U. Rehman, A. Sheikh, M.A.S. Abourehab, P. Kesharwani, Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy, (September 2022). https://doi.org/10.1080/09205063.2022.2121592. Journal of Biomaterials Science, Polymer Edition **(Impact factor: 3.682)**
208. S.G. Alamdari, A. Alibakhshi, M. de la Guardia, B. Baradaran, R. Mohammadzadeh, M. Amini, P. Kesharwani, A. Mokhtarzadeh, F. Oroojalian, A. Sahebkar, Conductive and Semiconductive Nanocomposite-Based Hydrogels for Cardiac Tissue Engineering, Adv. Healthc. Mater. 11 (September 2022) 2200526. https://doi.org/10.1002/ADHM.202200526. **(Impact factor: 11.092)**
209. A. Dey, G. Singhvi, A. Puri, P. Kesharwani, S.K. Dubey, An insight into photodynamic therapy towards treating major dermatological conditions, J. Drug Deliv. Sci. Technol. 76 (August 2022) 103751. https://doi.org/10.1016/J.JDDST.2022.103751. **(Impact factor: 5)**
210. A. Mhaske, S. Singh, M.A.S. Abourehab, A. Kumar, P. Kesharwani, R. Shukla, Recent pharmaceutical engineered trends as theranostics for Japanese encephalitis, Process Biochem. 122 (August 2022) 115–127. https://doi.org/10.1016/J.PROCBIO.2022.08.017. **(Impact factor: 4.885)**

211. S. Ataei, P. Kesharwani, A. Sahebkar, Berberine: Ins and outs of a nature-made PCSK9 inhibitor, EXCLI J. 21 (August 2022) 1099–1110. https://doi.org/10.17179/EXCLI2022-5234. **(Impact factor: 4.002)**
212. S.M. Hosseinikhah, F. Gheybi, S.A. Moosavian, M.A. Shahbazi, M.R. Jaafari, M. Sillanpää, P. Kesharwani, S.H. Alavizadeh, A. Sahebkar, Role of exosomes in tumour growth, chemoresistance and immunity: state-of-the-art, Https://Doi.Org/10.1080/1061186X.2022.2114000. (August 2022). https://doi.org/10.1080/1061186X.2022.2114000. Journal of Drug Targeting **(Impact factor: 5.016)**
213. V. Singh, K. Eljaaly, S. Md, N.A. Alhakamy, **P. Kesharwani***, Triblock copolymeric drug delivery as an emerging nanocarrier for treatment of infectious diseases, J. Drug Deliv. Sci. Technol. 75 (August 2022) 103691. https://doi.org/10.1016/J.JDDST.2022.103691. **(Impact factor: 5)**
214. V. Singh, A. Sheikh, M.A.S. Abourehab, **P. Kesharwani***, Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment, Biosens. 2022, Vol. 12, Page 617. 12 (August 2022) 617. https://doi.org/10.3390/BIOS12080617. **(Impact factor: 5.743)**
215. S. Mukherjee, S. Mukherjee, M.A.S. Abourehab, A. Sahebkar, P. Kesharwani, Exploring dendrimer-based drug delivery systems and their potential applications in cancer immunotherapy, Eur. Polym. J. 177 (August 2022) 111471. https://doi.org/10.1016/J.EURPOLYMJ.2022.111471. **(Impact factor: 6)**
216. S. Singh, A. Numan, D. Sharma, R. Shukla, A. Alexander, G.K. Jain, F.J. Ahmad, P. Kesharwani, Epidemiology, virology and clinical aspects of hantavirus infections: an overview., Int. J. Environ. Health Res. (August 2021) 1–13. https://doi.org/10.1080/09603123.2021.1917527. **(Impact factor: 4.477)**
217. M. Sanati, A.R. Afshari, P. Kesharwani, V.N. Sukhorukov, A. Sahebkar, Recent trends in the application of nanoparticles in cancer therapy: The involvement of oxidative stress, J. Control. Release. 348 (August 2022) 287–304. https://doi.org/10.1016/J.JCONREL.2022.05.035. **(Impact factor: 11.467)**
218. N. Rahiman, Y. V. Markina, P. Kesharwani, T.P. Johnston, A. Sahebkar, Curcumin-based nanotechnology approaches and therapeutics in restoration of autoimmune diseases, J. Control. Release. 348 (August 2022) 264–286. https://doi.org/10.1016/J.JCONREL.2022.05.046. **(Impact factor: 11.467)**
219. Z. Jamshidi, M. Hashemi, R. Yazdian-Robati, · Leila Etemad, Z. Salmasi, P. Kesharwani, Effects of Boswellia species on viral infections with particular attention to SARS-CoV-2, Inflammopharmacology 2022. 1 (July 2022) 1–13. https://doi.org/10.1007/S10787-022-01037-4. **(Impact factor: 5.093)**
220. G. Mohammadi, M. Korani, H. Nemati, A.R. Nikpoor, K. Rashidi, K. Varmira, M. Abbasifard, P. Kesharwani, S. Korani, A. Sahebkar, Crocin-loaded nanoliposomes: Preparation, characterization, and evaluation of anti-inflammatory effects in an experimental model of adjuvant-induced arthritis, J. Drug Deliv. Sci. Technol. 74 (August 2022) 103618. https://doi.org/10.1016/J.JDDST.2022.103618. **(Impact factor: 5)**
221. A.K. Jain, S. Jain, M.A.S. Abourehab, P. Mehta, P. Kesharwani, An insight on topically applied formulations for management of various skin disorders. J. Biomater. Sci. Polym. Ed. (July 2022) 1–27. https://doi.org/10.1080/09205063.2022.2103625. **(Impact factor: 3.682)**
222. P. Kesharwani, R. Chadar, R. Shukla, G.K. Jain, G. Aggarwal, M.A.S. Abourehab, A. Sahebkar, Recent advances in multifunctional dendrimer-based nanoprobes for breast cancer theranostics,. J. Biomater. Sci. Polym. Ed. (July 2022) 1–39. https://doi.org/10.1080/09205063.2022.2103627. **(Impact factor: 3.682)**

223. M. Handa, A. Singh, D. Bisht, P. Kesharwani, R. Shukla, Potential of particle size less than 15 nm via olfactory region for direct brain delivery via intranasal route, Heal. Sci. Rev. 4 (July 2022) 100038. https://doi.org/10.1016/J.HSR.2022.100038.
224. M. Mahjoubin-Tehran, S.H. Aghaee-Bakhtiari, A. Sahebkar, R.K. Oskuee, P. Kesharwani, A. Jalili, In silico and experimental validation of a new modified arginine-rich cell penetrating peptide for plasmid DNA delivery, Int. J. Pharm. 624 (August 2022) 122005. https://doi.org/10.1016/J.IJPHARM.2022.122005. **(Impact factor: 6.51)**
225. S. Ahmad, N. Hasan, Fauziya, A. Gupta, A. Nadaf, L. Ahmad, M. Aqil, P. Kesharwani, Review on 3D printing in dentistry: conventional to personalized dental care, Https://Doi.Org/10.1080/09205063.2022.2099666. J. Biomater. Sci. Polym. Ed. (November 2022) 1–32. https://doi.org/10.1080/09205063.2022.2099666. **(Impact factor: 3.682)**
226. P. Gupta, A. Sheikh, M.A.S. Abourehab, P. Kesharwani, Amelioration of Full-Thickness Wound Using Hesperidin Loaded Dendrimer-Based Hydrogel Bandages, Biosensors, (June 2022), Vol. 12, Page 462. 12 (2022) 462. https://doi.org/10.3390/BIOS12070462. **(Impact factor: 5.743)**
227. F. Baratzadeh, A.E. Butler, P. Kesharwani, S.A. Moallem, A. Sahebkar, Effects of curcumin on low-density lipoprotein oxidation: From experimental studies to clinical practice, EXCLI J. 21 (June 2022) 840–851. https://doi.org/10.17179/EXCLI2022-4878. **(Impact factor: 4.002)**
228. N. Singh, M. Handa, V. Singh, P. Kesharwani, R. Shukla, Lymphatic targeting for therapeutic application using nanoparticulate systems, Https://Doi.Org/10.1080/1061186X.2022.2092741. (June 2022) J. Drug Target. 1–34. https://doi.org/10.1080/1061186X.2022.2092741. **(Impact factor: 5.016)**
229. F. Oroojalian, S. Karimzadeh, S. Javanbakht, M. Hejazi, B. Baradaran, T.J. Webster, A. Mokhtarzadeh, R.S. Varma, P. Kesharwani, A. Sahebkar, Current trends in stimuli-responsive nanotheranostics based on metal–organic frameworks for cancer therapy, Mater. Today. (June 2022). https://doi.org/10.1016/J.MATTOD.2022.05.024. **(Impact factor: 32.072)**
230. N. Vasdev, M. Handa, P. Kesharwani, R. Shukla, Rosemary oil low energy nanoemulsion: optimization, μrheology, in silico, in vitro, and ex vivo characterization, (June 2022). J. Biomater. Sci. Polym. Ed. https://doi.org/10.1080/09205063.2022.2088527. **(Impact factor: 3.682)**
231. A. Malaiya, M. Singhai, M. Singh, S.K. Prajapati, H. Choudhury, M. Fatima, A. Alexander, S.K. Dubey, K. Greish, P. Kesharwani, Recent Update on the Alzheimer's Disease Progression, Diagnosis and Treatment Approaches, Curr. Drug Targets. 23 (August 2022). https://doi.org/10.2174/1389450123666220526155144. **(Impact factor: 2.937)**
232. A. Nikhat, N. Hasan, Z. Iqbal, P. Kesharwani, S. Talegaonkar, Enhanced transdermal delivery of lutein via nanoethosomal gel: Formulation optimization, in-vitro evaluation, and in-vivo assessment, J. Drug Deliv. Sci. Technol. 73 (May 2022) 103447. https://doi.org/10.1016/J.JDDST.2022.103447. **(Impact factor: 5)**
233. S. Kumar Dubey, N. Dabholkar, U. Narayan Pal, G. Singhvi, N. Kumar Sharma, A. Puri, P. Kesharwani, Emerging innovations in cold plasma therapy against cancer: A paradigm shift, Drug Discov. Today. (May 2022). https://doi.org/10.1016/J.DRUDIS.2022.05.014. **(Impact factor: 8.369)**
234. A. Dhiman, M. Handa, M. Ruwali, D.P. Singh, **P. Kesharwani***, R. Shukla, Recent trends of natural based therapeutics for mitochondria targeting in Alzheimer's disease, Mitochondrion. 64 (March 2022) 112–124. https://doi.org/10.1016/J.MITO.2022.03.006. **(Impact factor: 4.160)**
235. A. Singh, R.R. Ujjwal, S. Naqvi, R.K. Verma, S. Tiwari, **P. Kesharwani***, R. Shukla, Formulation development of tocopherol polyethylene glycol nanoengineered polyamidoamine dendrimer for neuroprotection and treatment of Alzheimer disease, J. Drug Target. 2022; Aug;30(7):777-791. https://doi.org/10.1080/1061186X.2022.2063297. **(Impact factor: 5.121)**

236. S.K. Dubey, S. Parab, V.P.K. Achalla, A. Narwaria, S. Sharma, B.H. Jaswanth Gowda, **P. Kesharwani***, Microparticulate and nanotechnology mediated drug delivery system for the delivery of herbal extracts, J. Biomater. Sci. Polym. Ed. 2022 Aug;33(12):1531-1554. https://doi.org/10.1080/09205063.2022.2065408. **(Impact factor: 3.517)**
237. R. Bandaru, S.R. Rout, O.S. Kamble, S.K. Samal, B. Gorain, A. Sahebkar, F.J. Ahmed, **P. Kesharwani***, R. Dandela, Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment, Process Biochem. 118 (July 2022) 154–170. https://doi.org/10.1016/J.PROCBIO.2022.04.011. **(Impact factor: 3.757)**
238. A. Sheikh, S. Md, N.A. Alhakamy, **P. Kesharwani***, Recent development of aptamer conjugated chitosan nanoparticles as cancer therapeutics, Int. J. Pharm. 620 (April 2022) 121751. https://doi.org/10.1016/J.IJPHARM.2022.121751. **(Impact factor: 5.875)**
239. A. Shaikh, **P. Kesharwani***, V. Gajbhiye, Dendrimer as a momentous tool in tissue engineering and regenerative medicine, J. Control. Release. 346 (June 2022) 328–354. https://doi.org/10.1016/J.JCONREL.2022.04.008. **(Impact factor: 10.8)**
240. S. Leporatti, M.A. Alghamdi, A.N. Fallica, N. Virzì, **P. Kesharwani***, V. Pittalà, K. Greish, The Promise of Nanotechnology in Personalized Medicine, J. Pers. Med. 2022, Vol. 12, Page 673. 12 (May 2022) 673. https://doi.org/10.3390/JPM12050673. **(Impact factor: 4.945)**
241. B. Gorain, M. Pandey, N.H. Leng, C.W. Yan, K.W. Nie, S.J. Kaur, V. Marshall, S.P. Sisinthy, J. Panneerselvam, N. Molugulu, **P. Kesharwani**, H. Choudhury, Advanced drug delivery systems containing herbal components for wound healing, Int. J. Pharm. 617 (February 2022) 121617. https://doi.org/10.1016/J.IJPHARM.2022.121617. **(Impact factor: 5.875)**
242. L. Farhoudi, **P. Kesharwani**, M. Majeed, T.P. Johnston, A. Sahebkar, Polymeric nanomicelles of curcumin: Potential applications in cancer, Int. J. Pharm. 617 (February 2022) 121622. https://doi.org/10.1016/J.IJPHARM.2022.121622. **(Impact factor: 5.875)**
243. S.K. Dubey, A. Dey, G. Singhvi, M.M. Pandey, V. Singh, **P. Kesharwani***, Emerging trends of nanotechnology in advanced cosmetics, Colloids Surfaces B Biointerfaces. 214 (March 2022) 112440. https://doi.org/10.1016/J.COLSURFB.2022.112440. **(Impact factor: 5.8)**
244. S. Singh, H.M. Aldawsari, A. Alam, M.H.S. Alqarni, S. Ranjan, **P. Kesharwani***, Synthesis and antimicrobial activity of vancomycin–conjugated zinc coordination polymer nanoparticles against methicillin-resistant staphylococcus aureus, J. Drug Deliv. Sci. Technol. 70 (April 2022) 103255. https://doi.org/10.1016/J.JDDST.2022.103255. **(Impact factor: 5)**
245. B.H.J. Gowda, M.G. Ahmed, A. Sahebkar, Y. Riadi, R. Shukla, **P. Kesharwani***, Stimuli-Responsive Microneedles as a Transdermal Drug Delivery System: A Demand-Supply Strategy, Biomacromolecules. (March 2022) acs.biomac.1c01691. https://doi.org/10.1021/ACS.BIOMAC.1C01691. **(Impact factor: 6.988)**
246. S. Kumari, P.K. Choudhary, R. Shukla, A. Sahebkar, **P. Kesharwani***, Recent advances in nanotechnology based combination drug therapy for skin cancer, Journal of Biomaterials Science, Polymer Edition, (March 2022) 1–34. https://doi.org/10.1080/09205063.2022.2054399. **(Impact factor: 3.517)**
247. P. Khairnar, M. Soni, M. Handa, Y. Riadi, **P. Kesharwani***, R. Shukla, Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives, J. Drug Target. (March 2022) 1–11. https://doi.org/10.1080/1061186X.2022.2056187. **(Impact factor: 5.121)**
248. N. Hasan, M. Imran, A. Sheikh, S. Saad, G. Chaudhary, G.K. Jain, **P. Kesharwani***, F.J. Ahmad, Cannabis as a potential compound against various malignancies, legal aspects, advancement by exploiting nanotechnology and clinical trials, J. Drug Target. (February 2022) 1–17. https://doi.org/10.1080/1061186X.2022.2056188. **(Impact factor: 5.121)**

249. M. Fatima, A. Sheikh, N. Hasan, A. Sahebkar, Y. Riadi, **P. Kesharwani***, Folic acid conjugated poly(amidoamine) dendrimer as a smart nanocarriers for tracing, imaging, and treating cancers over-expressing folate receptors, Eur. Polym. J. 170 (March 2022) 111156. https://doi.org/10.1016/J.EURPOLYMJ.2022.111156. **(Impact factor: 6)**
250. A. Mahmoudi, P. Kesharwani, M. Majeed, Y. Teng, A. Sahebkar, Recent advances in nanogold as a promising nanocarrier for curcumin delivery, Colloids Surfaces B Biointerfaces. (March 2022) 112481. https://doi.org/10.1016/J.COLSURFB.2022.112481. **(Impact factor: 5.8)**
251. AR Afshari, M Sanati, H Mollazadeh, **P Kesharwani**, TP Johnston, A. Sahebkarefgh. Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways. Seminars in Cancer Biology, Volume 86, Part 2, November 2022, Pages 860-872. https://doi.org/10.1016/j.semcancer.2022.01.008 **(Impact factor: 15.707)**
252. E. Mirhadi, M. Majeed, **P. Kesharwani**, A. Sahebkar. Reactive oxygen species-responsive drug delivery systems: a new approach in nanomedicine. Curr Med Chem. 2022;29(25):4320-4323. doi: 10.2174/0929867329666220127110654 (August 2022). **(Impact factor: 4.53)**
253. R. Taliyan, V. Kakoty, KC Sarathlal, SS Kharavtekar, CR Karennanavar, YK Choudhary, G Singhvi, Y Riadi , SK Dubey, **P Kesharwani***. Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease. Journal of Controlled Release, Volume 343, (January 2022), Pages 528-550 **(Impact factor: 10.8)**
254. M. Pashirzad, T. Sathyapalan, A. Sheikh, **P. Kesharwani***, A. Sahebkar. Cancer stem cells: An overview of the pathophysiological and prognostic roles in colorectal cancer. Process Biochemistry. Volume 115, (April 2022), Pages 19-29 **(Impact factor: 3.757)**
255. I. Khan, M.A. Tantray, H. Hamid, M. Sarwar Alam, K. Sharma, **P. Kesharwani**, Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates, Bioorg. Chem. 119 Bioorganic Chemistry, Volume 119, (February 2022), 105512 **(Impact factor: 5.275)**
256. D. Modi, J. Nirmal, M.H. Warsi, M. Bhatia, N. Hasan, **P. Kesharwani***, G.K. Jain, Formulation and development of tacrolimus-gellan gum nanoformulation for treatment of dry eye disease, Colloids Surfaces B Biointerfaces. 211 (March 2022) 112255. https://doi.org/10.1016/J.COLSURFB.2021.112255. **(Impact factor: 5.8)**
257. A. Parolia, R.A. Bapat, T. Chaubal, H.J. Yang, S. Panda, M. Mohan, A. Sahebkar, **P. Kesharwani***, Recent update on application of propolis as an adjuvant natural medication in management of gum diseases and drug delivery approaches, Process Biochem. 112 (January 2022) 254–268. https://doi.org/10.1016/J.PROCBIO.2021.12.009. (Impact factor: 3.717)
258. V.S. Madamsetty, S. Tavakol, S. Moghassemi, A. Dadashzadeh, J.D. Schneible, I. Fatemi, A. Shirvani, A. Zarrabi, F. Azedi, A. Dehshahri, A. Aghaei Afshar, K. Aghaabbasi, A. Pardakhty, R. Mohammadinejad, **P. Kesharwani***, Chitosan: A versatile bio-platform for breast cancer theranostics, J. Control. Release. 341 (January 2022) 733–752. https://doi.org/10.1016/J.JCONREL.2021.12.012. (Impact factor: 10.8)
259. S.K. Dubey, S. Parab, A. Alexander, M. Agrawal, V.P.K. Achalla, U.N. Pal, M.M. Pandey, **P. Kesharwani***, Cold atmospheric plasma therapy in wound healing, Process Biochem. 112 (January 2022) 112–123. https://doi.org/10.1016/J.PROCBIO.2021.11.017. (Impact factor: 3.717)
260. V. Singh, S. Md, N.A. Alhakamy, **P. Kesharwani***, Taxanes loaded polymersomes as an emerging polymeric nanocarrier for cancer therapy, Eur. Polym. J. 162 (January 2022) 110883. https://doi.org/10.1016/J.EURPOLYMJ.2021.110883. (Impact factor: 6)
261. A. Sheikh, S. Md, **P. Kesharwani***, Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer, Biomed. Pharmacother. 146 (February 2022) 112530. https://doi.org/10.1016/J.BIOPHA.2021.112530. (Impact factor: 6.529)

262. Malani M, Salunke P, Kulkarni S, Jain GK, Sheikh A, **Kesharwani P***, Nirmal J. Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. J Biomater Sci Polym Ed. (January 2022); 33(1):110-136. (Impact factor: 3.517)
263. Mohammad, V. Garg, N. Jayabalan, M.H. Warsi, D. Pandita, **P. Kesharwani***, G.K. Jain, Topical tacrolimus progylcosomes nano-vesicles as a potential therapy for experimental dry eye syndrome, J Pharm Sci. (February 2022); 111(2):479-484. https://doi.org/10.1016/J.XPHS.2021.09.038. (Impact factor: 3.534)
264. B. Dhawan, G. Akhter, D.H. Hamid, **P. Kesharwani**, M.S. Alam, Benzoxaboroles: New emerging and versatile scaffold with a plethora of pharmacological activities, Journal of Molecular Structure, Volume 1252, 15 March 2022, 132057 https://doi.org/10.1016/J.MOLSTRUC.2021.132057. (Impact factor: 3.196)
265. P. Kesharwani*, R. Chadar, A. Sheikh, W.Y. Rizg, A.Y. Safhi, CD44-Targeted Nanocarrier for Cancer Therapy, Front. Pharmacol. 12 (31 March 2022) 3986. https://doi.org/10.3389/FPHAR.2021.800481/BIBTEX. **(Impact factor: 5.988)**
266. P. Sengupta, H. Choudhury, S. Dutta, S. Jacob, P. Kesharwani, B. Gorain, Current Strategies in Breast Cancer Therapy: Role of Epigenetics and Nanomedicine, Part. Part. Syst. Charact. 39 (27 March 2022) 2100276. https://doi.org/10.1002/PPSC.202100276. **(Impact factor: 3.467)**
267. N. Hasan, M. Imran, D. Jain, A. Shamim, S. Beg, P. Kesharwani*, G. Jain, F.J. Ahmad, Rapid analytical method development and validation for the simultaneous estimation of 5-Fluorouracil and Cannabidiol in plasma and lipid-based nanoformulations, Curr. Anal. Chem. 18 (7 November 2022). https://doi.org/10.2174/1573411018666220304085236. **(Impact factor: 2.374)**
268. T. Jamialahmadi, M. Banach, W. Almahmeed, P. Kesharwani, A. Sahebkar, Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis, Arch. Med. Sci. 18 (May 2022) 1372–1377. https://doi.org/10.5114/AOMS/152685. **(Impact factor: 3.707)**
269. T. Jamialahmadi, Ž. Reiner, M. Alidadi, W. Almahmeed, P. Kesharwani, K. Al-Rasadi, A.H. Eid, M. Rizzo, A. Sahebkar, Effect of Bariatric Surgery on Intima Media Thickness: A Systematic Review and Meta-Analysis, J. Clin. Med. 2022, Vol. 11, Page 6056. 11 (13 October 2022) 6056. https://doi.org/10.3390/JCM11206056. **(Impact factor: 4.964)**
270. N. Sabouni, H.Z. Marzouni, S. Palizban, S. Meidaninikjeh, P. Kesharwani, T. Jamialahmadi, A. Sahebkar, Role of curcumin and its nanoformulations in the treatment of neurological diseases through the effects on stem cells, Https://Doi.Org/10.1080/1061186X.2022.2141755. (2022) 1–34. https://doi.org/10.1080/1061186X.2022.2141755. **(Impact factor: 3.467)**
271. M.; Fatima, A.; Sheikh, M.A.S.; Abourehab, P. Kesharwani*, M. Fatima, A. Sheikh, M.A.S. Abourehab, P. Kesharwani, Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer, Pharm. 2022, Vol. 14, Page 2432. 14 (20 November 2022) 2432. https://doi.org/10.3390/PHARMACEUTICS14112432. **(Impact factor: 5.016)**
272. V. Kailasam, S.S. Cheruvu, M. Malani, S.M. Sai Kameswari, P. Kesharwani*, J. Nirmal, Recent advances in novel formulation approaches for tacrolimus delivery in treatment of various ocular diseases, J. Drug Deliv. Sci. Technol. 78 (December 2022) 103945. https://doi.org/10.1016/J.JDDST.2022.103945. **(Impact factor: 5)**
273. P. Musyuni, J. Bai, A. Sheikh, K.S. Vasanthan, G.K. Jain, M.A.S. Abourehab, V. Lather, G. Aggarwal, P. Kesharwani*, D. Pandita, Precision medicine: Ray of hope in overcoming cancer multidrug resistance, Drug Resist. Updat. 65 (December 2022) 100889. https://doi.org/10.1016/J.DRUP.2022.100889. **(Impact factor: 22.841)**

274. Z. Khan, A. Alhalmi, N. Tyagi, W.U. Khan, A. Sheikh, M.A.S. Abourehab, K. Kohli, P. Kesharwani*, Folic acid engineered sulforaphane loaded microbeads for targeting breast cancer, (21 November 2022) 1–20. https://doi.org/10.1080/09205063.2022.2144692. **(Impact factor: 3.682)**
275. P. Kesharwani*, M. Fatima, V. Singh, A. Sheikh, W.H. Almalki, V. Gajbhiye, A. Sahebkar, Itraconazole and Difluorinated-Curcumin Containing Chitosan Nanoparticle Loaded Hydrogel for Amelioration of Onychomycosis, Biomimetics 2022, Vol. 7, Page 206. 7 (21 November 2022) 206. https://doi.org/10.3390/BIOMIMETICS7040206. **(Impact factor: 3.743)**
276. A.A. Khan, R. Janardhanan, J. Kishore, R. Karwasra, S. Saeed, B.C. Das, N. Hasan, W. H. Almalki, P. Kesharwani, W. Selvamurthy. Unani System of medicine and it's development in contemporary healthcare: a comprehensive review. Journal of Pharmaceutical Negative Results, 2022 Nov. 12:634-45. DOI: https://doi.org/10.47750/pnr.2022.13.S09.71
277. D. Minno, T. Jamialahmadi, M. Abbasifard, Ž. Reiner, P. Kesharwani, A. Sahebkar, The Effect of Bariatric Surgery on Circulating Levels of Monocyte Chemoattractant Protein-1: A Systematic Review and Meta-Analysis, J. Clin. Med. 2022, Vol. 11, Page 7021. 11 (28 November 2022) 7021. https://doi.org/10.3390/JCM11237021. **(Impact factor: 4.964)**
278. G.K. Jain, J. Sharma, N. Modi, T. Kothari, N. Hasan, N. Sharma, A. Sheikh, A. Sahebkar, **P. Kesharwani***, Nano-progesterone: An improvised therapeutic approach, J. Pharm. Negat. Results. 13 (17 November 2022) 1315–1320. https://doi.org/10.47750/PNR.2022.13.S09.157.

Year 2023:

279. M.J. Javid-Naderi, A. Mahmoudi, P. Kesharwani*, T. Jamialahmadi, A. Sahebkar, Recent advances of nanotechnology in the treatment and diagnosis of polycystic ovary syndrome, J. Drug Deliv. Sci. Technol. 79 (January 2023) 104014. https://doi.org/10.1016/J.JDDST.2022.104014. **(Impact factor: 5)**
280. M. Abedi, S.M. Haftcheshmeh, R. Bashar, P. Kesharwani*, M. Samadi, A. Sahebkar, Rabies vaccine: Recent update and comprehensive review of in vitro and in vivo studies, Process Biochem. 124 (January 2023) 201–220. https://doi.org/10.1016/J.PROCBIO.2022.11.011. **(Impact factor: 4.885)**
281. M. Shahriari, P. Kesharwani, T.P. Johnston, A. Sahebkar, Anticancer potential of curcumin-cyclodextrin complexes and their pharmacokinetic properties, Int. J. Pharm. 631 (25 January 2023) 122474. https://doi.org/10.1016/J.IJPHARM.2022.122474. **(Impact factor: 6.51)**
282. M. Fatima, R. Karwasra, W.H. Almalki, A. Sahebkar, P. Kesharwani*, Galactose engineered nanocarriers: Hopes and hypes in cancer therapy, Eur. Polym. J. 183 (19 January 2023) 111759. https://doi.org/10.1016/J.EURPOLYMJ.2022.111759. **(Impact factor: 6)**
283. R. Grover, S. Drall, N. Poonia, G. Kumar Jain, G. Aggarwal, V. Lather, P. Kesharwani*, D. Pandita, R.K. Goyal, CD44 and CD133 aptamer directed nanocarriers for cancer stem cells targeting, Eur. Polym. J. 183 (19 January 2023) 111770. https://doi.org/10.1016/J.EURPOLYMJ.2022.111770. **(Impact factor: 6)**
284. N. Parveen, M.A.S. Abourehab, R. Shukla, P.V. Thanikachalam, G.K. Jain, P. Kesharwani*, Immunoliposomes as an emerging nanocarrier for breast cancer therapy, Eur. Polym. J. 184 (7 February 2023) 111781. https://doi.org/10.1016/J.EURPOLYMJ.2022.111781. **(Impact factor: 6)**
285. U. Rehman, M.A.S. Abourehab, A. Alexander, P. Kesharwani*, Polymeric micelles assisted combinatorial therapy: Is it new hope for pancreatic cancer?, Eur. Polym. J. 184 (7 February 2023) 111784. https://doi.org/10.1016/J.EURPOLYMJ.2022.111784. **(Impact factor: 6)**
286. M. Khosrojerdi, E. Gumpricht, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Is Curcumin a Safe and Effective Therapeutic in the Treatment Against Oral Lichen Planus?, Curr. Med. Chem. 30 (23 December 2022). https://doi.org/10.2174/0929867330666221202150727. **(Impact factor: 4.740)**

287. N. Hasan, M. Imran, M. Nadeem, D. Jain, K. Haider, M. Moshahid Alam Rizvi, A. Sheikh, P. Kesharwani*, G. Kumar jain, F. Jalees Ahmad, Formulation and development of novel lipid-based combinatorial advanced nanoformulation for effective treatment of non-melanoma skin cancer, Int. J. Pharm. 632 (5 February 2023) 122580. https://doi.org/10.1016/J.IJPHARM.2022.122580. **(Impact factor: 6.51)**
288. P. Kesharwani*, A. Sheikh, M.A.S. Abourehab, R. Salve, V. Gajbhiye, A combinatorial delivery of survivin targeted siRNA using cancer selective nanoparticles for triple negative breast cancer therapy, J. Drug Deliv. Sci. Technol. 80 (February 2023) 104164. https://doi.org/10.1016/J.JDDST.2023.104164. **(Impact factor: 5)**
289. B.H.J. Gowda, M.G. Ahmed, U. Hani, P. Kesharwani, S. Wahab, K. Paul, Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art review, Int. J. Pharm. 632 (5 February 2023) 122591. https://doi.org/10.1016/J.IJPHARM.2023.122591. **(Impact factor: 6.51)**
290. Z. Liu, N. Parveen, U. Rehman, A. Aziz, A. Sheikh, M.A. S. Abourehab, W. Guo, J. Huang, Z. Wang, P. Kesharwani*. Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer. Mol Cancer 22, 8 (2023). https://doi.org/10.1186/s12943-022-01696-5 **(Impact factor: 41.444)**
291. L. Zeng, B.H.J. Gowda, M.G. Ahmed, M.A.S. Abourehab, Z-S. Chen, C. Zhang, J. Li, P. Kesharwani*. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol Cancer 22, 10 (2023). https://doi.org/10.1186/s12943-022-01708-4 **(Impact factor: 41.444)**
292. X. Fu, U. Rehman, L. Wei, Z.-S. Chen, M.A.S. Abourehab, P. Kesharwani*, Z.-H. Cheng, Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond, Drug Resist. Updat. 68 (2023) 100935. https://doi.org/10.1016/J.DRUP.2023.100935. **(Impact factor: 22.841)**
293. M. Abavisani, R. Khayami, M. Hoseinzadeh, M. Kodori, P. Kesharwani*, A. Sahebkar, CRISPR-Cas system as a promising player against bacterial infection and antibiotic resistance, Drug Resist. Updat. 68 (2023) 100948. https://doi.org/10.1016/J.DRUP.2023.100948. **(Impact factor: 22.841)**
294. S. Chamani, M. Moossavi, A. Naghizadeh, M. Abbasifard, P. Kesharwani, T. Sathyapalan, A. Sahebkar, Modulatory properties of curcumin in cancer: A narrative review on the role of interferons, Phyther. Res. 37 February (2023) 1003–1014. https://doi.org/10.1002/PTR.7734. **(Impact factor: 6.388)**
295. A. Hosseini, M.S. Alavi, A.R. Shahraki, A. Rajabian, A.R. Afshari, P. Kesharwani, A. Sahebkar, Psidium guajava induces cytotoxicity in human malignant glioblastoma cell line: Role of reactive oxygen species, Toxicol. Vitr. 89 June (2023) 105567. https://doi.org/10.1016/J.TIV.2023.105567. **(Impact factor: 3.685)**
296. T.T. Dongsar, T.S. Dongsar, M.A.S. Abourehab, N. Gupta, P. Kesharwani, Emerging application of magnetic nanoparticles for breast cancer therapy, Eur. Polym. J. 187 April (2023) 111898. https://doi.org/10.1016/J.EURPOLYMJ.2023.111898. **(Impact factor: 6)**
297. M. Atefi, Z. Heidari, M. Shojaei, G. Askari, P. Kesharwani, M. Bagherniya, A. Sahebkar, Does quinoa (Chenopodium quinoa) consumption improve blood glucose, body weight and body mass index? A systematic review and dose-response meta-analysis of clinical trials., Curr. Med. Chem. 30 (2023). https://doi.org/10.2174/0929867330666230227151852. **(Impact factor: 5.046)**
298. S. Ranjbari, A. Mohammadinejad, T.P. Johnston, P. Kesharwani*, R.K. Oskuee, M. Rezayi, A. Sahebkar, Molecularly-imprinted polymers for the separation and detection of curcumin, Eur. Polym. J. 189 (2023) 111916. https://doi.org/10.1016/J.EURPOLYMJ.2023.111916. **(Impact factor: 6)**
299. N. Tiwari, D. Kumar, A. Priyadarshani, G.K. Jain, G. Mittal, P. Kesharwani, G. Aggarwal, Recent progress in polymeric biomaterials and their potential applications in skin regeneration and wound

care management, J. Drug Deliv. Sci. Technol. 82 (2023) 104319. https://doi.org/10.1016/J.JDDST.2023.104319. **(Impact factor: 5)**

300. N. Parveen, M.A.S. Abourehab, P.V. Thanikachalam, R.K. Khar, P. Kesharwani, Nanocrystals as an emerging nanocarrier for the management of dermatological diseases, Colloids Surfaces B Biointerfaces. 225 (2023) 113231. https://doi.org/10.1016/J.COLSURFB.2023.113231. **(Impact factor: 5.8)**
301. W. Qin, J. Chandra, M.A.S. Abourehab, N. Gupta, Z.S. Chen, P. Kesharwani*, H.L. Cao, New opportunities for RGD-engineered metal nanoparticles in cancer, Mol. Cancer. 22 (25 May 2023) 87. https://doi.org/10.1186/S12943-023-01784-0/FIGURES/8. **(Impact factor: 41.444)**
302. M. Narwade, A. Shaikh, K.R. Gajbhiye, P. Kesharwani*, V. Gajbhiye, Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery, Biomater. Res. 2023 271. 27 (6 May 2023) 1–36. https://doi.org/10.1186/S40824-023-00365-Y. **(Impact factor: 11.3)**
303. A. Narmani, R. Jahedi, E. Bakhshian-Dehkordi, S. Ganji, M. Nemati, R. Ghahramani-Asl, K. Moloudi, S.M. Hosseini, H. Bagheri, P. Kesharwani*, A. Khani, B. Farhood, A. Sahebkar, Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy, Https://Doi.Org/10.1080/17425247.2023.2223941. (9 June 2023) 1–18. https://doi.org/10.1080/17425247.2023.2223941. **(Impact factor: 8.129)**
304. J. Chandra, N. Molugulu, S. Annadurai, S. Wahab, R. Karwasra, S. Singh, R. Shukla, P. Kesharwani*, Hyaluronic acid-functionalized lipoplexes and polyplexes as emerging nanocarriers for receptor-targeted cancer therapy, Environ. Res. 233 (15 September 2023) 116506. https://doi.org/10.1016/J.ENVRES.2023.116506. **(Impact factor: 8.431)**
305. K. Malhotra, A. Malik, W.H. Almalki, A. Sahebkar, P. Kesharwani*, Reactive oxygen species and its manipulation strategies in cancer treatment., Curr. Med. Chem. 30 (24 June 2023). https://doi.org/10.2174/0929867330666230609110455. **(Impact factor: 5.016)**
306. Z. Mokhtari, E. Seyedhashemi, M. Eftekhari, S. Ghasemi, A. Sabouri, K. Abbaszadeh-Goudarzi, M. Abuali, H. Azimi, P. Kesharwani*, H. Pourghadamyari, A. Sahebkar, Enhancement of cisplatin-induced apoptosis by saffron in human lung cancer cells, J. Trace Elem. Med. Biol. 79 (September 2023) 127229. https://doi.org/10.1016/J.JTEMB.2023.127229. **(Impact factor: 6.51)**
307. M. Ataei, E. Gumpricht, P. Kesharwani*, T. Jamialahmadi, A. Sahebkar, Recent advances in curcumin-based nanoformulations in diabetes, Https://Doi.Org/10.1080/1061186X.2023.2229961. (24 June 2023) 1–44. https://doi.org/10.1080/1061186X.2023.2229961. **(Impact factor: 5.016)**
308. T. Sonam Dongsar, T. Tsering Dongsar, N. Molugulu, S. Annadurai, S. Wahab, N. Gupta, P. Kesharwani*, Targeted therapy of breast tumor by PLGA-based nanostructures: The versatile function in doxorubicin delivery, Environ. Res. 233 (15 September 2023) 116455. https://doi.org/10.1016/J.ENVRES.2023.116455. **(Impact factor: 8.431)**
309. P.V. Thanikachalama, S. Ramamurthy, P. Mallapu, S.R. Varma, J. Narayanan, M.A. Abourehab, P. Kesharwani*, Modulation of IL-33/ST2 signaling as a potential new therapeutic target for cardiovascular diseases, Cytokine Growth Factor Rev. (Preproof 2023). https://doi.org/10.1016/J.CYTOGFR.2023.06.003. **(Impact factor: 17.66)**
310. P. Kesharwani*, R. Ma, L. Sang, M. Fatima, A. Sheikh, M.A.S. Abourehab, N. Gupta, Z.-S. Chen, Y. Zhou, Gold nanoparticles and gold nanorods in the landscape of cancer therapy, Mol. Cancer 2023 221. 22 (21 June 2023) 1–31. https://doi.org/10.1186/S12943-023-01798-8. **(Impact factor: 41.444)**
311. N. Hasan, M. Imran, A. Sheikh, N. Tiwari, A. Jaimini, P. Kesharwani*, G.K. Jain, F.J. Ahmad, Advanced multifunctional nano-lipid carrier loaded gel for targeted delivery of 5-flurouracil and cannabidiol against non-melanoma skin cancer, Environ. Res. 233 (15 September 2023) 116454. https://doi.org/10.1016/J.ENVRES.2023.116454. **(Impact factor: 8.431)**

312. M.S. Khan, A. Sheikh, M.A.S. Abourehab, N. Gupta, P. Kesharwani*, Understanding the theranostic potential of quantum dots in cancer management, Mater. Today Commun. 36 (August 2023) 106424. https://doi.org/10.1016/J.MTCOMM.2023.106424. **(Impact factor: 3.662)**
313. A. Mahmoudi, S.H. Alavizadeh, S.A. Hosseini, P. Meidany, M. Doagooyan, Y. Abolhasani, Z. Saadat, F. Amani, P. Kesharwani*, F. Gheybi, A. Sahebkar, Harnessing aptamers against COVID-19: A therapeutic strategy, Drug Discov. Today. 28 (August 2023) 103663. https://doi.org/10.1016/J.DRUDIS.2023.103663. **(Impact factor: 8.369)**
314. M. Rahmanian, F. Oroojalian, E. Pishavar, P. Kesharwani*, A. Sahebkar, Nanogels, nanodiscs, yeast cells, and metallo-complexes-based curcumin delivery for therapeutic applications, Eur. Polym. J. 196 (11 September 2023) 112215. https://doi.org/10.1016/J.EURPOLYMJ.2023.112215. **(Impact factor: 6)**
315. Z. Kiani, S. Amini, G. Askari, P. Kesharwani, M. Bagherniya, A. Sahebkar, The effect of phytochemicals in prediabetic patients: A systematic review of randomized controlled trials, Phyther. Res. (29 May 2023). https://doi.org/10.1002/PTR.7892. **(Impact factor: 6.388)**
316. Sristi, M. Fatima, A. Sheikh, W.H. Almalki, S. Talegaonkar, S.K. Dubey, M.C.I.M. Amin, A. Sahebkar, P. Kesharwani*, Recent advancement on albumin nanoparticles in treating lung carcinoma, Https://Doi.Org/10.1080/1061186X.2023.2205609. 31 (preprint 2023) 486–499. https://doi.org/10.1080/1061186X.2023.2205609. **(Impact factor: 5.016)**
317. M. Keikha, P. Kesharwani*, A. Sahebkar, Contradictory perspectives on the transmission route of human monkeypox during the 2022 outbreak, Microb. Pathog. 181 (August 2023) 106178. https://doi.org/10.1016/J.MICPATH.2023.106178. **(Impact factor: 3.848)**
318. T. Jamialahmadi, L.E. Simental-Mendia, G. Zengin, W. Almahmeed, P. Kesharwani*, A. Sahebkar, Meta-analysis of the impact of bariatric surgery on circulating TMAO levels as a predictor of cardiovascular disease risk., Curr. Med. Chem. 30 (23 May 2023). https://doi.org/10.2174/0929867330666230523155750. **(Impact factor: 4.740)**
319. F. Zahedipour, S.A. Hosseini, M. Astaneh, P. Kesharwani, M.R. Jaafari, A. Sahebkar, Application of VEGF/VEGFR peptide vaccines in cancer: A systematic review of clinical trials, Crit. Rev. Oncol. Hematol. 187 (July 2023) 104032. https://doi.org/10.1016/J.CRITREVONC.2023.104032. **(Impact factor: 6.625)**
320. H. Baharara, P. Kesharwani, T.P. Johnston, A.H. Sahebkar, Therapeutic potential of phytochemicals for cystic fibrosis, BioFactors. (16 May 2023). https://doi.org/10.1002/BIOF.1960. **(Impact factor: 6.438)**
321. M. Sanati, A.R. Afshari, S. Aminyavari, P. Kesharwani*, T. Jamialahmadi, A. Sahebkar, RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy, J. Drug Deliv. Sci. Technol. 84 (June 2023) 104562. https://doi.org/10.1016/J.JDDST.2023.104562. **(Impact factor: 5)**
322. D. Khayatan, S.M. Razavi, Z.N. Arab, Y. Hosseini, A. Niknejad, S. Momtaz, A.H. Abdolghaffari, T. Sathyapalan, T. Jamialahmadi, P. Kesharwani*, A. Sahebkar, Superoxide dismutase: a key target for the neuroprotective effects of curcumin, Mol. Cell. Biochem. (11 May 2023) 1–13. https://doi.org/10.1007/S11010-023-04757-5/METRICS. **(Impact factor: 3.842)**
323. Fauziya, A. Gupta, A. Nadaf, S. Ahmad, N. Hasan, M. Imran, A. Sahebkar, G.K. Jain, P. Kesharwani*, F.J. Ahmad, Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies, Med. Oncol. 2023 406. 40 (10 May 2023) 1–23. https://doi.org/10.1007/S12032-023-02018-5. **(Impact factor: 3.738)**
324. J. Ahamed, B.H. Jaswanth Gowda, W.H. Almalki, N. Gupta, A. Sahebkar, P. Kesharwani*, Recent advances in nanoparticle-based approaches for the treatment of brain tumors: Opportunities and challenges, Eur. Polym. J. 193 (19 July 2023) 112111. https://doi.org/10.1016/J.EURPOLYMJ.2023.112111. **(Impact factor: 6)**

325. E. Mirhadi, P. Kesharwani*, T.P. Johnston, A. Sahebkar, Nanomedicine-mediated therapeutic approaches for pulmonary arterial hypertension, Drug Discov. Today. 28 (June 2023) 103599. https://doi.org/10.1016/J.DRUDIS.2023.103599. **(Impact factor: 8.369)**
326. S. Jagdale, M. Narwade, A. Sheikh, S. Md, R. Salve, V. Gajbhiye, P. Kesharwani*, K.R. Gajbhiye, GLUT1 transporter-facilitated solid lipid nanoparticles loaded with anti-cancer therapeutics for ovarian cancer targeting, Int. J. Pharm. 637 (25 April 2023) 122894. https://doi.org/10.1016/J.IJPHARM.2023.122894. **(Impact factor: 6.51)**
327. S. Reka, A. Sheikh, W.H. Almalki, P. Kesharwani*, P.V. Thanikachalam, A review of various analytical methods for the estimation of olanzapine: An antipsychotic drug, Biomed. Chromatogr. 37 (28 March 2023) e5632. https://doi.org/10.1002/BMC.5632. **(Impact factor: 1.911)**
328. M. Sanati, A.R. Afshari, S.S. Ahmadi, P. Kesharwani*, A. Sahebkar, Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat, Biochim. Biophys. Acta - Mol. Basis Dis. 1869 (August 2023) 166720. https://doi.org/10.1016/J.BBADIS.2023.166720. **(Impact factor: 6.633)**
329. S. Aziz Hazari, H. Kaur, R. Karwasra, M.A.S. Abourehab, A. Ali Khan, P. Kesharwani*, An overview of topical lipid-based and polymer-based nanocarriers for treatment of psoriasis, Int. J. Pharm. 638 (10 May 2023) 122938. https://doi.org/10.1016/J.IJPHARM.2023.122938. **(Impact factor: 6.51)**
330. V. Kakoty, S. Kc, S. Kumari, C.H. Yang, S.K. Dubey, A. Sahebkar, P. Kesharwani*, R. Taliyan, Brain insulin resistance linked Alzheimer's and Parkinson's disease pathology: An undying implication of epigenetic and autophagy modulation, Inflammopharmacology 2023 312. 31 (23 March 2023) 699–716. https://doi.org/10.1007/S10787-023-01187-Z. **(Impact factor: 5.093)**
331. H. Yaribeygi, M. Maleki, S.L. Atkin, P. Kesharwani, T. Jamialahmadi, A. Sahebkar, Anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors in COVID-19, IUBMB Life. (27 March 2023). https://doi.org/10.1002/IUB.2719. **(Impact factor: 4.709)**
332. N. Parveen, A. Sheikh, M.A.S. Abourehab, R. Karwasra, S. Singh, P. Kesharwani*, Self-nanoemulsifying drug delivery system for pancreatic cancer, Eur. Polym. J. 190 (25 May 2023) 111993. https://doi.org/10.1016/J.EURPOLYMJ.2023.111993. **(Impact factor: 6)**
333. T.T. Dongsar, T.S. Dongsar, N. Gupta, W.H. Almalki, A. Sahebkar, P. Kesharwani*, Emerging potential of 5-Fluorouracil-loaded chitosan nanoparticles in cancer therapy, J. Drug Deliv. Sci. Technol. 82 (April 2023) 104371. https://doi.org/10.1016/J.JDDST.2023.104371. **(Impact factor: 5)**
334. F. Maghool, M.H. Emami, R. Alipour, S. Mohammadzadeh, N. Sereshki, S.A.E. Dehkordi, A. Fahim, Z. Tayarani-Najaran, A. Sheikh, P. Kesharwani*, A. Sahebkar, Rescue effect of curcumin against copper toxicity, J. Trace Elem. Med. Biol. 78 (July 2023) 127153. https://doi.org/10.1016/J.JTEMB.2023.127153. **(Impact factor: 3.995)**
335. A. Sheikh, M.A.S. Abourehab, A.S. Tulbah, P. Kesharwani*, Aptamer-grafted, cell membrane-coated dendrimer loaded with doxorubicin as a targeted nanosystem against epithelial cellular adhesion molecule (EpCAM) for triple negative breast cancer therapy, J. Drug Deliv. Sci. Technol. 86 (Sep 2023) 104745. https://doi.org/10.1016/J.JDDST.2023.104745. **(Impact factor 5)**
336. B.H.J. Gowda, M.G. Ahmed, S.A. Alshehri, S. Wahab, L.K. Vora, R.R. Singh Thakur, P. Kesharwani*, The cubosome-based nanoplatforms in cancer therapy: Seeking new paradigms for cancer theranostics, Environ. Res. 237 (Nov 2023) 116894. https://doi.org/10.1016/J.ENVRES.2023.116894. **(Impact factor 8.3)**
337. N. Parveen, A. Sheikh, N. Molugulu, S. Annadurai, S. Wahab, P. Kesharwani*, Drug permeation enhancement, efficacy, and safety assessment of azelaic acid loaded SNEDDS hydrogel to

overcome the treatment barriers of atopic dermatitis, Environ. Res. 236 (Nov 2023) 116850. https://doi.org/10.1016/J.ENVRES.2023.116850. **(Impact factor 8.3)**

338. S.K. Jha, M. Imran, L.A. Jha, N. Hasan, V.K. Panthi, K.R. Paudel, W.H. Almalki, Y. Mohammed, P. Kesharwani*, A Comprehensive review on Pharmacokinetic Studies of Vaccines: Impact of delivery route, carrier-and its modulation on immune response, Environ. Res. 236 (Nov 2023) 116823. https://doi.org/10.1016/J.ENVRES.2023.116823. **(Impact factor 8.3)**
339. M.S. Khan, B.H.J. Gowda, N. Nasir, S. Wahab, M.R. Pichika, A. Sahebkar, P. Kesharwani*, Advancements in dextran-based nanocarriers for treatment and imaging of breast cancer, Int. J. Pharm. 643 (Aug 2023) 123276. https://doi.org/10.1016/J.IJPHARM.2023.123276. **(Impact factor 5.8)**
340. L. Siddiqui, N. Hasan, P.K. Mishra, N. Gupta, A.T. Singh, A. Madaan, M. Jaggi, S. Saad, A. Ekielski, Z. Iqbal, P. Kesharwani, S. Talegaonkar, CD44 mediated colon cancer targeting mutlifaceted lignin nanoparticles: Synthesis, in vitro characterization and in vivo efficacy studies, Int. J. Pharm. 643 (Aug 2023) 123270. https://doi.org/10.1016/J.IJPHARM.2023.123270. **(Impact factor 5.8)**
341. S.M. Ahmadi, S. Amirkhanloo, R. Yazdian-Robati, H. Ebrahimi, F.H. Pirhayati, W.H. Almalki, P. Ebrahimnejad, P. Kesharwani, Recent advances in novel miRNA mediated approaches for targeting breast cancer, Https://Doi.Org/10.1080/1061186X.2023.2240979. Journal of Drug Targeting (Aug 2023). https://doi.org/10.1080/1061186X.2023.2240979. **(Impact factor 4.5)**
342. S. Fathi, N. Jalilzadeh, M. Amini, D. Shanebandi, B. Baradaran, F. Oroojalian, A. Mokhtarzadeh, P. Kesharwani, A. Sahebkar, Surface plasmon resonance-based oligonucleotide biosensor for Salmonella Typhi detection, Anal. Biochem. 677 (Sep 2023) 115250. https://doi.org/10.1016/J.AB.2023.115250. **(Impact factor 2.9)**
343. J. Chandra, N. Hasan, N. Nasir, S. Wahab, P.V. Thanikachalama, A. Sahebkar, F.J. Ahmad, P. Kesharwani, Nanotechnology-empowered strategies in treatment of skin cancer, Environ. Res. 235 (Oct 2023) 116649. https://doi.org/10.1016/J.ENVRES.2023.116649. **(Impact factor 8.3)**
344. Mohammad, U.A. Khan, Z. Saifi, J. Bora, M.H. Warsi, M.A.S. Abourehab, G.K. Jain, P. Kesharwani, A. Ali, Intranasal inorganic cerium oxide nanoparticles ameliorate oxidative stress induced motor manifestations in haloperidol-induced parkinsonism, Inflammopharmacology 2023. (July 2023) 1–15. https://doi.org/10.1007/S10787-023-01274-1. **(Impact factor 5.8)**
345. L. Etemad, Z. Salmasi, S.A. Moosavian Kalat, M. Moshiri, J. Zamanian, P. Kesharwani, A. Sahebkar, An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy, Environ. Res. 234 (Oct 2023) 116572. https://doi.org/10.1016/J.ENVRES.2023.116572. **(Impact factor 8.3)**
346. M. Rahmanian, A. Ghahremani, P. Kesharwani, F. Oroojalian, A. Sahebkar, Nanomedicine innovations in spinal cord injury management: Bridging the gap, Environ. Res. 235 (Oct 2023) 116563. https://doi.org/10.1016/J.ENVRES.2023.116563. **(Impact factor 8.3)**
347. A. Sahebkar, Z. Heidari, Z. Kiani, M. Atefi, A. Zareie, M. Shojaei, G. Askari, P. Kesharwani, M. Bagherniya, The efficacy of dietary approaches to stop hypertension (DASH) diet on lipid profile: A systematic review and meta-analysis of clinical controlled trials., Curr. Med. Chem. 31 (2023). https://doi.org/10.2174/0929867331666230706102406. **(Impact factor 4.1)**
348. M. Khosrojerdi, Ž. Reiner, N. Vatanparast, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Roles of PCSK9 in the Pathogenesis of Periodontal Disease, Curr. Med. Chem. 31 (2023). https://doi.org/10.2174/0929867331666230809100021 (September 28, 2023) **(Impact factor: 4.6)**.
349. A. Sheikh, S.A. Hazari, N. Molugulu, S.A. Alshehri, S. Wahab, A. Sahebkar, P. Kesharwani, Hyaluronic acid engineered gallic acid embedded chitosan nanoparticle as an effective delivery

system for treatment of psoriasis, Environ. Res. 238 (2023) 117086. https://doi.org/10.1016/J.ENVRES.2023.117086 (1 December 2023) **(Impact factor: 8.3)**.

350. F. Gheybi, F. Rajabian, Z. Tayarani-Najaran, A.R. Adibi, S.H. Alavizadeh, P. Kesharwani, A. Sahebkar, Liposomal silymarin anti-oxidative and anti-apoptotic features in lung cells: An implication in cadmium toxicity, J. Trace Elem. Med. Biol. 80 (2023) 127291. https://doi.org/10.1016/J.JTEMB.2023.127291 (December 2023) **(Impact factor: 3.5)**.
351. T. Jamialahmadi, Ž. Reiner, M. Matbou Riahi, P. Kesharwani, A.H. Eid, Z. Tayarani-Najaran, A. Sahebkar, The Effects of Statin Therapy on Circulating Levels of Trimethylamine N-oxide: A Systematic Review and Meta-analysis., Curr. Med. Chem. 31 (2023). https://doi.org/10.2174/0109298673245069231010065055. (19 October, 2023) **(Impact factor: 4.6)**.
352. M. Sameer, Y. Arif, A. Aqil, A. Nadaf, K. Rafiya, N. Hasan, P. Kesharwani, F.J. Ahmad, Carbon nanodots as a remedial nanovesicles for drug delivery, Eur. Polym. J. 200 (2023) 112515. https://doi.org/10.1016/J.EURPOLYMJ.2023.112515. (22 November 2023) **(Impact factor: 6)**
353. N. Hasan, A. Nadaf, M. Imran, U. Jiba, A. Sheikh, W.H. Almalki, S.S. Almujri, Y.H. Mohammed, P. Kesharwani, F.J. Ahmad, Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches, Mol. Cancer 2023 221. 22 (2023) 1–70. https://doi.org/10.1186/S12943-023-01854-3. (06 October 2023) **(Impact factor: 41.44)**
354. M. Banazadeh, B. Behnam, N.A. Ganjooei, B.H.J. Gowda, P. Kesharwani, A. Sahebkar, Curcumin-based nanomedicines: A promising avenue for brain neoplasm therapy, J. Drug Deliv. Sci. Technol. 89 (2023) 105040. https://doi.org/10.1016/J.JDDST.2023.105040. (November 2023) **(Impact factor: 5)**
355. K.R. Gajbhiye, R. Salve, M. Narwade, A. Sheikh, P. Kesharwani, V. Gajbhiye, Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics, Mol. Cancer 2023 221. 22 (2023) 1–44. https://doi.org/10.1186/S12943-023-01849-0. (03 October 2023) **(Impact factor: 41.44)**
356. S.A. Hazari, A. Sheikh, M.A.S. Abourehab, A.S. Tulbah, P. Kesharwani*, Self-assembled Gallic acid loaded lecithin-chitosan hybrid nanostructured gel as a potential tool against imiquimod-induced psoriasis, Environ. Res. 234 (2023) 116562. https://doi.org/10.1016/J.ENVRES.2023.116562. (1 October 2023) **(Impact factor: 8.3)**.
357. H. Yaribeygi, M. Maleki, T. Jamialahmadi, N.K. Shakhpazyan, P. Kesharwani*, A. Sahebkar, Nanoparticles with SGLT2 inhibitory activity: Possible benefits and future, Diabetes Metab. Syndr. Clin. Res. Rev. 17 (2023) 102869. https://doi.org/10.1016/J.DSX.2023.102869. (October 2023) **(Impact factor:10)**
358. M. Sanati, A.R. Afshari, P. Kesharwani*, A. Sahebkar, Recent advances in codelivery of curcumin and siRNA as anticancer therapeutics, Eur. Polym. J. 198 (2023) 112444. https://doi.org/10.1016/J.EURPOLYMJ.2023.112444. (17 October 2023) **(Impact factor: 6)**
359. M. Beygi, F. Oroojalian, S.S. Hosseini, A. Mokhtarzadeh, P. Kesharwani, A. Sahebkar, Recent progress in functionalized and targeted polymersomes and chimeric polymeric nanotheranostic platforms for cancer therapy, Prog. Mater. Sci. 140 (2023) 101190. https://doi.org/10.1016/J.PMATSCI.2023.101190. (December 2023) **(Impact factor: 48.32)**
360. T. Jamialahmadi, Ž. Reiner, M.M. Riahi, S.A. Emami, Z. Tayarani-Najaran, S. Salehabadi, P. Kesharwani, K. Al-Rasadi, A. Sahebkar, Statins and portal hypertension: a systematic review and meta-analysis of randomized controlled trials., Curr. Med. Chem. 31 (2023). https://doi.org/10.2174/0929867331666230918114451. (18 Sep 2023) (Impact factor: 4.6)

361. R.A. Bapat, S. V. Bedia, A.S. Bedia, H.J. Yang, S. Dharmadhikari, A.M. Abdulla, T. V. Chaubal, P.R. Bapat, S.S. Abullais, S. Wahab, P. Kesharwani*, Current appraises of therapeutic applications of nanocurcumin: A novel drug delivery approach for biomaterials in dentistry, Environ. Res. 238 (2023) 116971. https://doi.org/10.1016/J.ENVRES.2023.116971. (1 December 2023) **(Impact factor: 8.3)**
362. S. Tangri, N. Hasan, J. Kaur, Fauziya, Mohammad, S. Maan, P. Kesharwani*, F.J. Ahmad, Drug loaded bioglass nanoparticles and their coating for efficient tissue and bone regeneration, J. Non. Cryst. Solids. 616 (2023) 122469. https://doi.org/10.1016/j.jnoncrysol.2023.122469 (15 September 2023) **(Impact factor: 3.5)**.
363. H.S. Sardou, S.E. Nazari, M. Abbaspour, A. Akhgari, A. Sheikh, P. Kesharwani*, A. Sahebkar, Nano-curcumin formulations for targeted therapy of colorectal cancer, J. Drug Deliv. Sci. Technol. 88 (2023) 104943. https://doi.org/10.1016/J.JDDST.2023.104943. (October 2023) **(Impact factor: 5)**.
364. N. Hasan, M. Imran, D. Jain, S.K. Jha, A. Nadaf, A. Chaudhary, K. Rafiya, L.A. Jha, W.H. Almalki, Y. Mohammed, P. Kesharwani*, F.J. Ahmad, Advanced targeted drug delivery by bioengineered white blood cell-membrane camouflaged nanoparticulate delivery nanostructures, Environ. Res. 238 (2023) 117007. https://doi.org/10.1016/J.ENVRES.2023.117007. (1 December 2023) **(Impact factor: 8.431)**.
365. M. Daliri, L.E. Simental-Mendía, T. Jamialahmadi, P. Kesharwani, Ž. Reiner, A. Sahebkar, Effect of Statins on Superoxide Dismutase Level: A Systematic Review., Curr. Med. Chem. 31 (2023). https://doi.org/10.2174/0929867331666230831145809. (31 Aug 2023) **(Impact factor: 4.6)**.
366. A. Verma, P. Patel, W.H. Almalki, A. Sahebkar, B. Das Kurmi, P. Kesharwani*, Recent advances in drug delivery approaches for rheumatoid arthritis., Curr. Med. Chem. 31 (2023). https://doi.org/10.2174/0929867331666230815112818. (15 Aug 2023) **(Impact factor: 4.6)**.
367. S.K. Singh, S. Singh, R. Kumar, P. Rana, A. Sharma, R. Karwasra, P. Kesharwani*, A. Sahebkar, Influence of Vitamin D level on inflammatory and prognostic markers in COVID-19 - A retrospective study., Recent Adv. Food, Nutr. Agric. 14 (2023). https://doi.org/10.2174/2772574X14666230808095649. (08 Aug 2023).
368. A.R. Afshari, M. Sanati, P. Kesharwani, A. Sahebkar, Recent Advances in Curcumin-Based Combination Nanomedicines for Cancer Therapy, J. Funct. Biomater. 2023, Vol. 14, Page 408. 14 (2023) 408. https://doi.org/10.3390/JFB14080408. (2 August 2023) **(Impact factor: 4.8)**.
369. H. Yaribeygi, M. Maleki, S.L. Atkin, P. Kesharwani, T. Jamialahmadi, A. Sahebkar, Anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors in COVID-19, IUBMB Life. (2023). https://doi.org/10.1002/IUB.2719 (27 March 2023) **(Impact factor: 4.6)**.
370. F. Heidarian, S.H. Alavizadeh, M.R. Kalantari, S.J. Hoseini, H.K. Farshchi, M.R. Jaafari, M. Doagooyan, A. Bemidinezhad, P. Kesharwani, A. Sahebkar, F. Gheybi, Ellagic acid nanoliposomes potentiate therapeutic effects of PEGylated liposomal doxorubicin in melanoma: An in vitro and in vivo study, J. Drug Deliv. Sci. Technol. 93 (2024) 105396. https://doi.org/10.1016/J.JDDST.2024.105396. **(Impact factor: 5)**
371. M.A. Barkat, N. Hasan, M.Z. Hassan, Y.I. Asiri, A. Nadaf, F.J. Ahmad, P. Kesharwani, Formulation development of methotrexate lipid-based nanogel for treatment of skin cancer, Colloids Surfaces A Physicochem. Eng. Asp. (2024) 133571. https://doi.org/10.1016/J.COLSURFA.2024.133571. **(Impact factor: 5.2)**
372. A. Mahmoudi, M. Rostami, M. Mahdi Hajihasani, V.N. Sukhorukov, P. Kesharwani, A. Sahebkar, siRNA-mediated gene silencing for non-alcoholic fatty liver disease: A comprehensive

review of molecular targets, Eur. Polym. J. 208 (2024) 112866. https://doi.org/10.1016/J.EURPOLYMJ.2024.112866. **(Impact factor: 6)**

373. P.M. Moghadam, S.H. Alavizadeh, S.R. Rasouli, E. Oskoueian, A.A. Momtazi-Borojeni, P. Kesharwani, F. Gheybi, E. Karimi, A. Sahebkar, Adjuvant therapy with topical silymarin nanomicelles attenuates skin and hair depigmentation in a C57/BL6 mouse model of vitiligo, J. Drug Deliv. Sci. Technol. 94 (2024) 105508. https://doi.org/10.1016/J.JDDST.2024.105508. **(Impact factor: 5)**
374. E. Mirhadi, M. Mirhadi, P. Kesharwani, A. Sahebkar, Therapeutic potential of organosulfur compounds in pulmonary hypertension, PharmaNutrition. 27 (2024) 100382. https://doi.org/10.1016/J.PHANU.2024.100382. **(Impact factor: 3.2)**
375. E. Mirhadi, W. Almahmeed, P. Kesharwani, A. Sahebkar, Plant-derived phenolic acids in the treatment of pulmonary hypertension: A review of the underlying mechanisms, PharmaNutrition. 27 (2024) 100381. https://doi.org/10.1016/J.PHANU.2024.100381. **(Impact factor: 3.2)**
376. H.S. Sardou, M. Abbaspour, A. Akhgari, P. Kesharwani, A. Sahebkar, Colon-targeted delivery systems of budesonide as second-line therapy in inflammatory bowel disease, J. Drug Deliv. Sci. Technol. 93 (2024) 105472. https://doi.org/10.1016/J.JDDST.2024.105472. **(Impact factor: 5)**
377. S. Awasthi, N. Hasan, M. Nadeem, M.A. Rizvi, K. Alam, P. Kesharwani, F.J. Ahmad, Optimized formulation of berberine hydrochloride loaded nanoemulgel for management of skin cancer, Colloids Surfaces A Physicochem. Eng. Asp. 687 (2024) 133406. https://doi.org/10.1016/J.COLSURFA.2024.133406. **(Impact factor: 5.2)**
378. K. Paul, B.H.J. Gowda, U. Hani, R.S. Chandan, S. Mohanto, M.G. Ahmed, S. Ashique, P. Kesharwani, Traditional Uses, Phytochemistry, and Pharmacological Activities of Coleus amboinicus: A Comprehensive Review., Curr. Pharm. Des. 30 (2024). https://doi.org/10.2174/0113816128283267240130062600. **(Impact factor: 3.1)**
379. R.K. Bandaru, L. Giri, P. Kesharwani, R. Dandela, Drug-drug salts of Naftopidil with non-steroidal anti-inflammatory drugs for potential multi-drug therapy, Colloids Surfaces A Physicochem. Eng. Asp. 682 (2024) 132835. https://doi.org/10.1016/J.COLSURFA.2023.132835. **(Impact factor: 5.2)**
380. U. Rehman, A. Sheikh, A. Alsayari, S. Wahab, P. Kesharwani, Hesperidin-loaded cubogel as a novel therapeutic armamentarium for full-thickness wound healing, Colloids Surfaces B Biointerfaces. 234 (2024) 113728. https://doi.org/10.1016/J.COLSURFB.2023.113728. **(Impact factor: 5.8)**
381. B.H.J. Gowda, M.G. Ahmed, M.A.A. Almoyad, S. Wahab, W.H. Almalki, P. Kesharwani, Nanosponges as an Emerging Platform for Cancer Treatment and Diagnosis, Adv. Funct. Mater. (2023) 2307074. https://doi.org/10.1002/ADFM.202307074. **(Impact factor: 19)**
382. M. Atefi, Z. Heidari, M. Shojaei, G. Askari, P. Kesharwani, M. Bagherniya, A. Sahebkar, Does Quinoa (Chenopodium quinoa) Consumption Improve Blood Glucose, Body Weight and Body Mass Index? A Systematic Review and Dose-Response Meta-Analysis of Clinical Trials, Curr. Med. Chem. 31 (2023) 502–513. https://doi.org/10.2174/0929867330666230227151852. **(Impact factor: 4.1)**
383. M. Sameer Khan, B.H. Jaswanth Gowda, N. Hasan, G. Gupta, T. Singh, S. Md, P. Kesharwani, Carbon nanotube-mediated platinum-based drug delivery for the treatment of cancer: Advancements and future perspectives, Eur. Polym. J. 206 (2024) 112800. https://doi.org/10.1016/J.EURPOLYMJ.2024.112800. **(Impact factor: 6)**
384. G.K. Jain, V. Raina, R. Grover, J. Sharma, M.H. Warsi, G. Aggarwal, P. Kesharwani, Revisiting the significance of nano-vitamin D for food fortification and therapeutic application, Drug Dev. Ind. Pharm. (2024). https://doi.org/10.1080/03639045.2023.2301478. **(Impact factor: 3.4)**

385. O.T. Khaire, A. Mhaske, A.G. Prasad, W.H. Almalki, N. Srivastava, P. Kesharwani, R. Shukla, State-of-the-art drug delivery system to target the lymphatics, J. Drug Target. (2024). https://doi.org/10.1080/1061186X.2024.2309671. **(Impact factor: 4.5)**
386. T. Sonam Dongsar, T. Tsering Dongsar, G. Gupta, A. Alsayari, S. Wahab, P. Kesharwani, PLGA nanomedical consignation: A novel approach for the management of prostate cancer, Int. J. Pharm. 652 (2024) 123808. https://doi.org/10.1016/J.IJPHARM.2024.123808. **(Impact factor: 5.8)**
387. M. Beygi, F. Oroojalian, S. Azizi-Arani, S.S. Hosseini, A. Mokhtarzadeh, P. Kesharwani, A. Sahebkar, Multifunctional Nanotheranostics for Overcoming the Blood–Brain Barrier, Adv. Funct. Mater. (2024) 2310881. https://doi.org/10.1002/ADFM.202310881. **(Impact factor: 19)**
388. H.S. Sardou, P.R. Vosough, M. Abbaspour, A. Akhgari, P. Kesharwani, A. Sahebkar, Colon delivery of resveratrol for the treatment of inflammatory bowel disease, J. Drug Deliv. Sci. Technol. 92 (2024) 105315. https://doi.org/10.1016/J.JDDST.2023.105315. **(Impact factor: 5)**
389. G. Singh, P. Kesharwani, G. Kumar Singh, S. Kumar, A. Putta, G. Modi, Ferroptosis and its modulators: A raising target for cancer and Alzheimer's disease, Bioorg. Med. Chem. 98 (2024) 117564. https://doi.org/10.1016/J.BMC.2023.117564. **(Impact factor: 3.5)**
390. M.R. Donthi, A. Butreddy, R.N. Saha, P. Kesharwani, S.K. Dubey, Leveraging spray drying technique for advancing biologic product development–A mini review, Heal. Sci. Rev. 10 (2024) 100142. https://doi.org/10.1016/J.HSR.2023.100142.
391. S.A. Khan, W.H. Almalki, S. Arora, P. Kesharwani, Recent approaches for the treatment of uveal melanoma: Opportunities and challenges, Crit. Rev. Oncol. Hematol. 193 (2024) 104218. https://doi.org/10.1016/J.CRITREVONC.2023.104218. **(Impact factor: 6.2)**
392. U. Hani, B.H.J. Gowda, N. Haider, K. Ramesh, K. Paul, S. Ashique, M.G. Ahmed, S. Narayana, S. Mohanto, P. Kesharwani, Nanoparticle-Based Approaches for Treatment of Hematological Malignancies: a Comprehensive Review, AAPS PharmSciTech. 24 (2023) 1–24. https://link.springer.com/article/10.1208/s12249-023-02670-0 **(Impact factor: 3.3)**
393. S. Ranjbari, L.A. Ritchie, R. Arefinia, P. Kesharwani, A. Sahebkar, Biosensors to detect low-density lipoprotein and oxidized low-density lipoprotein in cardiovascular disease, Sensors Actuators A Phys. 365 (2024) 114841. https://doi.org/10.1016/J.SNA.2023.114841. **(Impact factor: 4.6)**
394. M.S. Khan, B.H. Jaswanth Gowda, W.H. Almalki, T. Singh, A. Sahebkar, P. Kesharwani, Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment, Drug Discov. Today. 29 (2024) 103819. https://doi.org/10.1016/J.DRUDIS.2023.103819. **(Impact factor: 7.8)**
395. A. Hasanpoor, M. Akaberi, P. Kesharwani, Z. Sobhani, A. Sahebkar, Drug interactions with Cannabis sativa: Mechanisms and clinical implication, Toxicol. Anal. Clin. (2023). https://doi.org/10.1016/J.TOXAC.2023.10.004. **(Impact factor: 0.6)**
396. M. Fatima, W.H. Almalki, T. Khan, A. Sahebkar, P. Kesharwani, Harnessing the Power of Stimuli-Responsive Nanoparticles as an Effective Therapeutic Drug Delivery System, Adv. Mater. (2024) 2312939. https://doi.org/10.1002/ADMA.202312939 **(Impact factor: 29.4)**
397. N. Omidkhah, F. Hadizadeh, R. Ghodsi, P. Kesharwani, A. Sahebkar, In Silico Evaluation of NO-Sartans against SARS-CoV-2, Curr. Drug Discov. Technol. 21 (2024). https://doi.org/10.2174/0115701638279362240223070810
398. M. Fatima, G. Gupta, S. Arora, A. Alsayari, S. Wahab, P. Kesharwani, Scouting the efficacy of targeted gold nanoparticles in the landscape of cancer therapy, Eur. Polym. J. 209 (2024) 112924. https://doi.org/10.1016/J.EURPOLYMJ.2024.112924 **(Impact factor: 6)**

399. A. Sheikh, P. Kesharwani, W.H. Almalki, S.S. Almujri, L. Dai, Z.S. Chen, A. Sahebkar, F. Gao, Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy, Nano-Micro Lett. 2024 161. 16 (2024) 1–56. https://doi.org/10.1007/S40820-024-01399-0. **(Impact factor: 26.6)**
400. A.R. Afshari, M. Sanati, S.S. Ahmadi, P. Kesharwani, A. Sahebkar, Harnessing the capacity of phytochemicals to enhance immune checkpoint inhibitor therapy of cancers: A focus on brain malignancies, Cancer Lett. 593 (2024) 216955. https://doi.org/10.1016/J.CANLET.2024.216955. **(Impact factor: 9.7)**
401. M.S. Khan, M. Fatima, G. Gupta, S. Md, P. Kesharwani, Recent progress in zein nanoparticles: A promising approach for advancing cancer therapy, J. Drug Deliv. Sci. Technol. 97 (2024) 105770. https://doi.org/10.1016/J.JDDST.2024.105770. **(Impact factor: 5)**
402. A. Sharma, D. Dheer, V. Puri, A. Alsayari, S. Wahab, P. Kesharwani, Insights of biopolymeric blended formulations for diabetic wound healing, Int. J. Pharm. 656 (2024) 124099. https://doi.org/10.1016/J.IJPHARM.2024.124099. **(Impact factor: 5.8)**
403. S. Ranjbari, M. Bolourinezhad, P. Kesharwani, M. Rezayi, A. Sahebkar, Applications of carbon nanotube biosensors: Sensing the future, J. Drug Deliv. Sci. Technol. 97 (2024) 105747. https://doi.org/10.1016/J.JDDST.2024.105747. **(Impact factor: 5)**
404. F.S. Hosseini, A. Ahmadi, P. Kesharwani, H. Hosseini, A. Sahebkar, Regulatory effects of statins on Akt signaling for prevention of cancers, Cell. Signal. 120 (2024) 111213. https://doi.org/10.1016/J.CELLSIG.2024.111213. **(Impact factor: 4.8)**
405. M. Sameer Khan, G. Gupta, A. Alsayari, S. Wahab, A. Sahebkar, P. Kesharwani, Advancements in liposomal formulations: A comprehensive exploration of industrial production techniques, Int. J. Pharm. 658 (2024) 124212. https://doi.org/10.1016/J.IJPHARM.2024.124212. **(Impact factor: 5.8)**
406. M.S. Ali, S.K. Jha, G. Gupta, A. Alsayari, S. Wahab, P. Kesharwani, Advancements in 5-fluorouracil-Loaded liposomal nanosystems: A comprehensive review on recent innovations in nanomedicine for cancer therapy, J. Drug Deliv. Sci. Technol. 96 (2024) 105730. https://doi.org/10.1016/J.JDDST.2024.105730. **(Impact factor: 5)**
407. S.G. Moghadam, M. Ebrahimpour, S.H. Alavizadeh, P. Kesharwani, A. Sahebkar, The association between oxidized low-density lipoprotein and cancer: An emerging targeted therapeutic approach?, Bioorg. Med. Chem. Lett. 106 (2024) 129762. https://doi.org/10.1016/J.BMCL.2024.129762. **(Impact factor: 2.7)**
408. S.G. Mohammadi, M. Kafeshani, M. Bagherniya, P. Kesharwani, A. Sahebkar, Exploring Curcumin's healing properties in the treatment of atopic dermatitis, Food Biosci. 59 (2024) 104144. https://doi.org/10.1016/J.FBIO.2024.104144. **(Impact factor: 5.2)**
409. P. Kesharwani, J. Chandra, S. Karim, G. Gupta, R. Karwasra, A. Sharma, αvβ3 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment, J. Drug Deliv. Sci. Technol. 96 (2024) 105663. https://doi.org/10.1016/J.JDDST.2024.105663. **(Impact factor: 5)**
410. H. Hatami, W. Almahmeed, P. Kesharwani, A. Sahebkar, Exploring the potential of 3D and 4D printing in advancing stent manufacturing for cardiovascular diseases, Eur. Polym. J. 212 (2024) 113035. https://doi.org/10.1016/J.EURPOLYMJ.2024.113035. **(Impact factor: 6)**
411. S. Azizuddin, M. Kazi, A. Nadaf, N. Hasan, A. Husain, P. Kesharwani, F.J. Ahmad, Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy, Process Biochem. 143 (2024) 44–59. https://doi.org/10.1016/J.PROCBIO.2024.04.002. **(Impact factor: 4.4)**

412. D. Chatterjee, S. Mansuri, N. Poonia, P. Kesharwani, V. Lather, D. Pandita, Therapeutic potential of various functional components presents within dragon fruit: A review, Hybrid Adv. 6 (2024) 100185. https://doi.org/10.1016/J.HYBADV.2024.100185.
413. S.A. Qureshi, K. Rafiya, S. Awasthi, A. Jain, A. Nadaf, N. Hasan, P. Kesharwani, F.J. Ahmad, Biomembrane camouflaged nanoparticles: A paradigm shifts in targeted drug delivery system, Colloids Surfaces B Biointerfaces. 238 (2024) 113893. https://doi.org/10.1016/J.COLSURFB.2024.113893. **(Impact factor: 5.8)**
414. A.A. Firouzjaei, A. Mahmoudi, W. Almahmeed, Y. Teng, P. Kesharwani, A. Sahebkar, Identification and analysis of the molecular targets of statins in colorectal cancer, Pathol. - Res. Pract. 256 (2024) 155258. https://doi.org/10.1016/J.PRP.2024.155258. **(Impact factor: 2.8)**
415. M. Rahmanian, F. Oroojalian, P. Kesharwani, A. Sahebkar, Current trends in triblock copolymer-based multifunctional nanotheranostics for cancer treatment, J. Drug Deliv. Sci. Technol. 99 (2024) 105985. https://doi.org/10.1016/J.JDDST.2024.105985. **(Impact factor: 5)**
416. H. Ahmadirad, H. pourghadamyari, M. Hadizadeh, M. Ali-Kheyl, O. Eslami, A. Afgar, A.R. Sayadi, M. Mahmoodi, P. Kesharwani, A. Sahebkar, Differential expression of long non-coding RNAs in colon cancer: Insights from transcriptomic analysis, Pathol. - Res. Pract. 261 (2024) 155477. https://doi.org/10.1016/J.PRP.2024.155477. **(Impact factor: 2.9)**
417. T. Tsering Dongsar, T. Sonam Dongsar, G. Gupta, P. Kesharwani, Innovative Strategies in Cancer Treatment: Harnessing Cuproptosis and Nanotechnology for Targeted Therapy, Drug Discov. Today. 29 (2024) 104104. https://doi.org/10.1016/J.DRUDIS.2024.104104. **(Impact factor: 7.8)**
418. F. Arghidash, M.J. Javid-Naderi, F. Gheybi, H. Gholamhosseinian, P. Kesharwani, A. Sahebkar, Exploring the multifaceted effects of silymarin on melanoma: Focusing on the role of lipid-based nanocarriers, J. Drug Deliv. Sci. Technol. 99 (2024) 105950. https://doi.org/10.1016/J.JDDST.2024.105950. **(Impact factor: 5)**
419. U.R. Bhandari, S.M. Danish, S. Ahmad, M. Ikram, A. Nadaf, N. Hasan, P. Kesharwani, F.J. Ahmad, New opportunities for antioxidants in amelioration of neurodegenerative diseases, Mech. Ageing Dev. 221 (2024) 111961. https://doi.org/10.1016/J.MAD.2024.111961. **(Impact factor: 5.3)**
420. R. Arefnezhad, S.S. Amin, A. Mohammdi, G. Ahmadi, A. Jahandideh, P. Goleij, H. Foroozand, H. Motedayyen, P. Kesharwani, A. Sahebkar, Quercetin and its nanoformulations as promising agents for lung cancer treatment: A focus on molecular mechanisms, J. Drug Deliv. Sci. Technol. 99 (2024) 105933. https://doi.org/10.1016/J.JDDST.2024.105933. **(Impact factor: 5)**
421. Nadaf, N. Hasan, Fauziya, S. Ahmad, A. Gupta, D. Jain, K. Imtiyaz, M. Moshahid Alam Rizvi, G.K. Jain, P. Kesharwani, F.J. Ahmad, Leucocyte membrane camouflaged poly-lactic-co-glycolic acid (PLGA) nanoparticles containing cannabidiol and paclitaxel against breast cancer therapy, Process Biochem. 142 (2024) 88–103. https://doi.org/10.1016/J.PROCBIO.2024.04.007. **(Impact factor: 3.7)**
422. Chaturvedi, G. Gupta, P. Kesharwani, R. Shukla, Revolutionizing periodontic care: Nano Dentistry's impact on inflammation management, J. Drug Deliv. Sci. Technol. 99 (2024) 105922. https://doi.org/10.1016/J.JDDST.2024.105922. **(Impact factor: 5)**
423. S.M. Hosseinikhah, F. Vahdat-Lasemi, L. Farhoudi, G. Gupta, P. Kesharwani, A. Sahebkar, RGD-decorated nanoparticles: Therapeutic potential beyond cancer, J. Drug Deliv. Sci. Technol. 98 (2024) 105924. https://doi.org/10.1016/J.JDDST.2024.105924. **(Impact factor: 5)**
424. Mahmoudi, A. Jalili, S.H. Aghaee-Bakhtiari, R.K. Oskuee, A. Mostafapour, P. Kesharwani, A. Sahebkar, MicroRNA delivery by arginine-rich cell-penetrating peptides: An investigation on expression and the cellular uptake mechanisms, Colloids Surfaces A Physicochem. Eng. Asp. 700 (2024) 134749. https://doi.org/10.1016/J.COLSURFA.2024.134749. **(Impact factor: 4.9)**
425. F. Oroojalian, F. Azizollahi, P. Kesharwani, A. Sahebkar, Stimuli-responsive nanotheranostic systems conjugated with AIEgens for advanced cancer bio-imaging and treatment, J. Control.

Release. 373 (2024) 766–802. https://doi.org/10.1016/J.JCONREL.2024.07.048. **(Impact factor: 10.5)**

426. S.K. Shahbaz, K. Koushki, O. Izadi, P.E. Penson, V.N. Sukhorukov, P. Kesharwani, A. Sahebkar, Advancements in Curcumin-Loaded PLGA Nanoparticle Delivery Systems: Progressive Strategies in Cancer Therapy, J. Drug Target. (2024). https://doi.org/10.1080/1061186X.2024.2389892. **(Impact factor: 4.3)**
427. Forouzanmehr, A.H. Hedayati, E. Gholami, M.A. Hemmati, M. Maleki, A.E. Butler, T. Jamialahmadi, P. Kesharwani, H. Yaribeygi, A. Sahebkar, Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits, Cell. Signal. 122 (2024) 111335. https://doi.org/10.1016/J.CELLSIG.2024.111335. **(Impact factor: 4.4)**
428. T.S. Dongsar, T.T. Dongsar, N. Nasir, S. Wahab, A. Sahebkar, G. Gupta, P. Kesharwani, Cuproptosis engineered nanomaterials: The silent warrior against cancer, Appl. Mater. Today. 39 (2024) 102305. https://doi.org/10.1016/J.APMT.2024.102305. **(Impact factor: 7.2)**
429. M. Mahjubin-Tehran, N. Khandan-Nasab, P. Kesharwani, A. Sahebkar, Dendrimer-Encapsulated Curcumin: Illuminating pathways to cancer treatment excellence, Eur. Polym. J. 218 (2024) 113358. https://doi.org/10.1016/J.EURPOLYMJ.2024.113358. **(Impact factor: 6)**
430. M. Abavisani, N. Faraji, S. Faraji, N. Ebadpour, P. Kesharwani, A. Sahebkar, A comprehensive review on utilizing CRISPR/Cas system for microbiome modification, Biochem. Eng. J. 211 (2024) 109443. https://doi.org/10.1016/J.BEJ.2024.109443. **(Impact factor: 3.7)**
431. Sharma, N. Jangra, D. Dheer, S.K. Jha, G. Gupta, V. Puri, P. Kesharwani, Understanding the journey of biopolymeric nanoformulations for oral drug delivery: Conventional to advanced treatment approaches, Eur. Polym. J. 218 (2024) 113338. https://doi.org/10.1016/J.EURPOLYMJ.2024.113338. **(Impact factor: 6)**
432. M. Pashirzad, P. Kesharwani, A. Sahebkar, The clinical prognostic significance of miR-140–5p expression in patients with cancer: A Meta and Bioinformatic analysis, Pathol. - Res. Pract. 261 (2024) 155475. https://doi.org/10.1016/J.PRP.2024.155475. **(Impact factor: 2.9)**
433. M. Aliyari, S.I. Hashemy, S.F. Hashemi, A. Reihani, P. Kesharwani, H. Hosseini, A. Sahebkar, Targeting the Akt signaling pathway: Exploiting curcumin's anticancer potential, Pathol. - Res. Pract. 261 (2024) 155479. https://doi.org/10.1016/J.PRP.2024.155479. **(Impact factor: 2.9)**
434. R. Solanki, M. Zubbair Malik, B. Alankar, F.J. Ahmad, R. Dohare, R. Chauhan, P. Kesharwani, H. Kaur, Identification of novel biomarkers and potential molecular targets for uterine cancer using network-based approach, Pathol. - Res. Pract. 260 (2024) 155431. https://doi.org/10.1016/J.PRP.2024.155431. **(Impact factor: 2.9)**
435. M. Mahjoubin-Tehran, S. Rezaei, P. Kesharwani, A. Sahebkar, Nanospheres for curcumin delivery as a precision nanomedicine in cancer therapy, J. Biomater. Sci. Polym. Ed. (2024). https://doi.org/10.1080/09205063.2024.2371186. **(Impact factor: 3.6)**
436. L. Akhileshwar Jha, M. Imran, J. Shrestha, H. Prasad Devkota, K. Bhattacharya, A. Alsayari, S. Wahab, S. Kumar Jha, K. Raj Paudel, P. Kesharwani, Effectiveness of phytoconstituents and potential of phyto-nanomedicines combination to treat osteoarthritis, Eur. Polym. J. 215 (2024) 113243. https://doi.org/10.1016/J.EURPOLYMJ.2024.113243. **(Impact factor: 6)**
437. A. Nadaf, U. Jiba, A. Chaudhary, N. Hasan, M. Adil, Y.H. Mohammed, P. Kesharwani, G.K. jain, F.J. Ahmad, Gamma scintigraphy in sensing drug delivery systems, Nucl. Eng. Technol. (2024). https://doi.org/10.1016/J.NET.2024.06.004. **(Impact factor: 2.6)**
438. A. Hussain, R. Kumari, F. Jabeen, I. Sulania, A. Dhillon, C. Ravikant, N. Hasan, P. Kesharwani, A.M. Siddiqui, Ion beam irradiation induced modification of PPy/ZnO nanocomposite thin films for supercapacitor applications, Surfaces and Interfaces. 51 (2024) 104647. https://doi.org/10.1016/J.SURFIN.2024.104647. **(Impact factor: 5.7)**
439. J.S. Unde, K. Ahirwar, A. Kumar, S. Ali Alshehri, S. Wahab, P. Kesharwani, R. Shukla, Manoeuvring the innovative drug delivery systems for veterinary therapeutics: Present day

demand, Eur. Polym. J. 215 (2024) 113244. https://doi.org/10.1016/J.EURPOLYMJ.2024.113244. **(Impact factor: 6)**

440. H. Hatami, M.M. Mojahedian, P. Kesharwani, A. Sahebkar, Advancing personalized medicine with 3D printed combination drug therapies: A comprehensive review of application in various conditions, Eur. Polym. J. 215 (2024) 113245. https://doi.org/10.1016/J.EURPOLYMJ.2024.113245. **(Impact factor: 6)**
441. M.S. Khan, M.Y. Alshahrani, S. Wahab, G. Gupta, P. Kesharwani, Evolution of artificial intelligence as a modern technology in advanced cancer therapy, J. Drug Deliv. Sci. Technol. 98 (2024) 105892. https://doi.org/10.1016/J.JDDST.2024.105892. **(Impact factor: 5)**
442. S. Qureshi, S. Anjum, M. Hussain, A. Sheikh, G. Gupta, M.A.A. Almoyad, S. Wahab, P. Kesharwani, A recent insight of applications of gold nanoparticles in glioblastoma multiforme therapy, Int. J. Pharm. 660 (2024) 124301. https://doi.org/10.1016/J.IJPHARM.2024.124301. **(Impact factor: 5.8)**
443. Y. Arif, Sameeya, N. Hasan, B.H.J. Gowda, G. Gupta, A. Alsayari, S. Wahab, P. Kesharwani, Advancements in dendrimer-based drug delivery for combinatorial cancer therapy, J. Drug Deliv. Sci. Technol. 97 (2024) 105755. https://doi.org/10.1016/J.JDDST.2024.105755. **(Impact factor: 5)**
444. L. Farhoudi, S. Maryam Hosseinikhah, F. Vahdat-Lasemi, V.N. Sukhorukov, P. Kesharwani, A. Sahebkar, Polymeric micelles paving the Way: Recent breakthroughs in camptothecin delivery for enhanced chemotherapy, Int. J. Pharm. 659 (2024) 124292. https://doi.org/10.1016/J.IJPHARM.2024.124292. **(Impact factor: 5.8)**
445. S. Rekha Rout, K.R. Manu, G. Kaur, K.G. Abishek, A. Alsayari, S. Wahab, P. Kesharwani, R. Dandela, Recent advances in drug delivery aspects using Organogel: Exploring a viscoelastic system as a platform for the next-generation therapeutics, Eur. Polym. J. 214 (2024) 113184. https://doi.org/10.1016/J.EURPOLYMJ.2024.113184. **(Impact factor: 6)**
446. N. Rastegar-Pouyani, T.S. Dongsar, M. Ataei, S. Hassani, E. Gumpricht, P. Kesharwani, A. Sahebkar, An overview of the efficacy of inhaled curcumin: a new mode of administration for an old molecule, Expert Opin. Drug Deliv. (2024). https://doi.org/10.1080/17425247.2024.2358880. **(Impact factor: 5)**

b. INTERNATIONAL BOOK PUBLISHED (as an Editor):

1. Mishra V, **Kesharwani P** (Editor), Mohd Amin MCI, Iyer AK. Nanotechnology-based approaches for targeting and delivery of drugs and genes. Elsevier, eBook ISBN: 9780128097182, Paperback ISBN: 9780128097175, Imprint: Academic Press, Published Date: 25th May 2017, Page Count: 552
2. **Kesharwani P (Editor)**. Nanotechnology Based Approaches for Tuberculosis Treatment. Elsevier, Academic Press, eBook ISBN: 9780128226117 ; Paperback ISBN: 9780128198117, Published Date: 2nd June 2019, Page Count: 370
3. **Kesharwani P** (Editor), Gupta U. Nanotechnology-based targeted drug delivery systems for brain tumors. Elsevier. eBook ISBN: 9780128122495, Paperback ISBN: 9780128122181, Imprint: Academic Press, Published Date: 24th April 2018, Page Count: 478
4. **Kesharwani P** (Editor). Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Elsevier, Academic Press, eBook ISBN: 9780128163672, Paperback ISBN: 9780128157206, Imprint: Academic Press, Published Date: 31st January 2019, Page Count: 340
5. **Kesharwani P (Editor),** Paknikar KM, Gajbhiye V. Polymeric Nanoparticles as a Promising Tool for Anti-cancer Therapeutics. Paperback ISBN: 9780128169636 ; eBook ISBN: 9780128173312, Imprint: Academic Press, Published Date: 1st July 2019, Page Count: 350

6. **Kesharwani P (Editor)**, Chopra S (Editor), Dasgupta A (Editor). Drug Discovery Targeting Drug-Resistant Bacteria. Elsevier, Academic Press, Paperback ISBN: 9780128184806 ; eBook ISBN: 9780128184813, Published Date: 1st May 2020, Page Count: 432
7. **Kesharwani P (Editor)**, Taurin S (Editor), Greish K (Editor). Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 540
8. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021), Paperback : 484 pages, ISBN: 9780128212516
9. **Kesharwani P (Editor),** Singh KK (Editor). Nanoparticle Therapeutics: Production Technologies, Types of Nanoparticles, and Regulatory Aspects. Publisher : Academic Press Inc (11 November 2021), Paperback : 672 pages, eBook ISBN: 9780128209189. Paperback ISBN: 9780128207574
10. **Kesharwani P (Editor),** Jain NK (Editor). Hybrid Nanomaterials for Drug Delivery (Woodhead Publishing Series in Biomaterials). 1st Edition - February 2, 2022, eBook ISBN: 9780323903561, Paperback ISBN: 9780323857543
11. **Kesharwani P (Editor).** Combination Drug Delivery Approach as an Effective Therapy for Various Diseases. Academic Press Inc. 1st Edition - March 27, 2022. Paperback ISBN: 9780323858731; eBook ISBN: 9780323858762.
12. **Kesharwani P (Editor).** Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for Drug Delivery (Micro & Nano Technologies) Paperback – Import, 1 March 2023. Prashant Kesharwani (Editor). Publisher: Elsevier - Health Sciences Division, No. of pages: 532, Published: March 2, 2022; Paperback ISBN: 9780323912150; eBook ISBN: 9780323914314
13. **Kesharwani P (Editor); Khaled Greish (Editor).** Polymeric Micelles for Drug Delivery (Woodhead Publishing Series in Biomaterials), Publisher: Woodhead Publishing (1 June 2022); Paperback : 510 pages, Paperback ISBN: 9780323898683; eBook ISBN: 9780323886291
14. **Kesharwani P (Editor).** Nanomaterials for Photodynamic Therapy (Woodhead Publishing Series in Biomaterials) Paperback – Import, 1 November 2022, Publisher: Woodhead Publishing (1 November 2022), Paperback: 485 pages, Paperback ISBN: 9780323855952; eBook ISBN: 9780323903547.
15. **Kesharwani P (Editor).** Emerging Applications of Carbon Nanotubes in Drug and Gene Delivery (Woodhead Publishing Series in Biomaterials), 1 October 2022, Publisher: Mosby (1 October 2022); Paperback : 500 pages, ISBN: 978-0-323-85199-2.
16. **Kesharwani P (Editor), Umesh Gupta (Editor).** Nanomedicine-Based Approaches for the Treatment of Dementia. Paperback – Import, 1 October 2022, Publisher: Academic Press Inc (1 October 2022), Paperback: 350 pages, ISBN-10: 0128243317, ISBN-13: 978-0128243312
17. "Effect of generation G on cancer targeting propensity of PPI dendrimer" published in LAP LAMBERT Academic Publishing House, 2015; ISBN: 978-3-8443-9285-2
18. "Relative study of cancer targeting potential of engineered dendrimer" published in LAP LAMBERT Academic Publishing House, 2015; ISBN: 978-3-659-51741-9
19. **Kesharwani P (Editor), Sunil Kumar Dubey (Editor).** Nanocosmetics: Delivery Approaches, Applications and Regulatory Aspects. Publisher: CRC Press, 2023, ISBN: 1000931447, 9781000931440, Length 422 pages.
20. **Kesharwani P (Editor)**, Gajbhiye V (Editor). Advances in Phytonanotechnology for Treatment of Various Diseases. Publisher: CRC Press; 1st edition (29 September 2023); ISBN-10: 1032137460; ISBN-13:978-1032137469; Hardcover: 372 pages.

21. Kesharwani P (Editor), Sahebkar A (Editor). Curcumin-Based Nanomedicines as Cancer Therapeutics; Publisher: Academic Press Inc (22 February 2024); Paperback: 490 pages; ISBN-10: 0443154120; ISBN-13: 978-044315412.
22. **Kesharwani P (Editor),** Gold Nanoparticles for Drug Delivery. Publisher: Academic Press Inc (29 November 2023), Paperback: 572 pages, ISBN-10: 0443190615, ISBN-13: 978-0443190612
23. **Kesharwani P (Editor), Gupta N (Editor)** Advances in Antiparasitic Therapies and Drug Delivery. Publisher: Academic Press Inc (21 November 2023), Paperback: 442 pages, ISBN-10: 0443151784, ISBN-13: 978-0443151781.
24. **Kesharwani P (Editor), Gupta N (Editor)** Recent Advances in Nanocarriers for Pancreatic Cancer Therapy. Publisher: Academic Press Inc (24 October 2023), Paperback: 494 pages, ISBN-10: 0443191425, ISBN-13: 978-0443191428.
25. **Kesharwani P (Editor),** Silver Nanoparticles for Drug Delivery. Publisher: Academic Press Inc (29 November 2023), Paperback: 500 pages, ISBN-10: 0443153434, ISBN-13: 978-0443153433.
26. **Kesharwani P (Editor),** Nanomedicine in Cancer Immunotherapy. Publisher: Academic Press Inc (16 January 2024), Paperback: 500 pages; ISBN-10: 0443187703; ISBN-13: 978-0443187704
27. **Kesharwani P (Editor), Jain NK (Editor).** Theranostics Nanomaterials in Drug Delivery. Publisher: Academic Press Inc (1 November 2024); Paperback: 450 pages; ISBN-10: 0443220441; ISBN-13: 978-0443220449.
28. **Kesharwani P (Editor), Thakur C.** Cancer Epigenetics and Nanomedicine: Targeting the Right Player via Nanotechnology. Publisher: Academic Press Inc (20 August 2024), Paperback: 550 pages; ISBN-10: 0443132097; ISBN-13: 978-0443132094
29. **Kesharwani P (Editor).** Design and Applications of Microneedles in Drug Delivery and Therapeutics Paperback – Import, 1 July 2024; Publisher: Academic Press Inc (1 July 2024), Paperback : 560 pages, ISBN-10: 0443138818; ISBN-13: 978-0443138812

c. BOOK CHAPTER PUBLISHED:

1. Mishra V, **Kesharwani P,** Jain NK. (2014). Functionalized polymeric nanoparticles for delivery of bioactives. Nanobiomedicine edited by the undersigned as its Chief Editor, and published by M/s Studium Press LLC, USA, 3, 91-123.
2. **Kesharwani P,** Mohd Amin MCI, Giri N, Jain A, Gajbhiye V. Dendrimers in targeting and delivery of drugs. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Publisher Academic Press (Elsevier) 2017 Pages 167-193.
3. Mohd Amin MCI, Butt AM, Amjad MW, **Kesharwani P**. Polymeric micelles for drug targeting and delivery. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes. Publisher Academic Press (Elsevier) 2017 Pages 363-383.
4. Meher JG, **Kesharwani P**, Chourasia M, Singh A, Chourasia M. Carbon nanotubes (CNTs): A novel drug delivery tool in brain tumor treatment. Nanotechnology-based Targeted Drug Delivery Systems for Brain Tumors. Publisher Academic Press (Elsevier) 2018 (in press).
5. Gorain B, Choudhury H, Pandey M, Mohd Amin MCI, Singh B, Gupta U, **Kesharwani P***. Dendrimers based drug delivery for brain tumor. Nanotechnology-based Targeted Drug Delivery Systems for Brain Tumors. Publisher Academic Press (Elsevier) 2018 (in press).
6. Gothwal A, Khan I, Kesharwani P, Chourasia MK, Gupta U. Micelles based drug delivery for brain tumor. Nanotechnology-based Targeted Drug Delivery Systems for Brain Tumors. Publisher Academic Press (Elsevier) 2018 (in press).
7. Thakur RRS, McMillan HL, Sheshala R, Tekko IA, Alshammari F, **Kesharwani P**. In situ forming phase-inversion injectable hydrogels for controlled drug release. Hydrogels: Design, Synthesis and Application in Drug Delivery and Regenerative Medicine. Edited by Thakur Raghu Raj Singh, Garry Laverty, Ryan Donnelly. CRC Press 2018.
8. Choudhury H, Gorain B, Madheswaran T, Pandey M, **Kesharwani P**, Tekade RK. Chapter 14 – Drug complexation: Implications in drug solubilization and oral bioavailability enhancement.

Dosage Form Design Considerations. Volume I, Advances in Pharmaceutical Product Development and Research 2018, Pages 473-512.

9. Gorain B, Choudhury H, Pandey M, Madheswaran T, **Kesharwani P**, Tekade RK. Chapter 11 – Drug–Excipient Interaction and Incompatibilities. Dosage Form Design Considerations. Volume I, Advances in Pharmaceutical Product Development and Research 2018, Pages 363-402.
10. Gorain B, Choudhury H, Pandey M, Nair AB, Mohd Amin MCQ, Molugulu N, Deb PK, Tripathi PK, Khurana S, Shukla R, Kohli K, **Kesharwani P**. Chapter 7-Dendrimer-based nanocarriers in lung cancer therapy. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Publisher Academic Press (Elsevier) 2019 Pages 161-192.
11. Choudhury H, Pandey M, Gorain B, Chatterjee B, Madheswaran T, Md S, Mak KK, Tambuwala M, Chourasia MK. **Kesharwani P**. Chapter 9- Nanoemulsions as Effective Carriers for the Treatment of Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Publisher Academic Press (Elsevier) 2019 Pages 217-247.
12. Gorain B, Bhattamishra SK, Choudhury H, Nandi U, Pandey M, **Kesharwani P**. Chapter 3 - Overexpressed Receptors and Proteins in Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Publisher Academic Press (Elsevier) 2019 39-75.
13. Shukla R, Singh A, Pardhi V, Kashyap K, Dubey SK, Dandela R, **Kesharwani P**. Chapter 11 - Dendrimer-Based Nanoparticulate Delivery System for Cancer Therapy. Polymeric Nanoparticles as a Promising Tool for Anti-cancer Therapeutics. Publisher Academic Press (Elsevier) 2019, Pages 233-55.
14. Shukla R, Handa M, Lokesh SB, Ruwali M, Kohli K, **Kesharwani P**. Chapter 18 - Conclusion and Future Prospective of Polymeric Nanoparticles for Cancer Therapy. Polymeric Nanoparticles as a Promising Tool for Anti-cancer Therapeutics. Publisher Academic Press (Elsevier) 2019 Pages 389-408.
15. Gorain B, Choudhury H, Pandey M. Kokare C, Khurana RK, Sehdev A, **Kesharwani P**. Chapter 6 - Polyester, Polyhydroxyalkanoate Nanoparticles as a Promising Tool for Anticancer Therapeutics. Publisher Academic Press (Elsevier) 2019 Pages 101-121.
16. Thakare R, **Kesharwani P**, Dasgupta A, Srinivas N, Chopra S. Chapter 1-Antibiotics: past, present, and future. Drug Discovery Targeting Drug-Resistant Bacteria. 1st Edition Publisher Academic Press (Elsevier) eBook ISBN: 9780128184813, 2020 Pages 1-8.
17. Thakare R, Kaul G, Shukla M, **Kesharwani P**, Dasgupta A, Chopra S. Chapter 5- Repurposing nonantibiotic drugs as antibacterials. 1st Edition Publisher Academic Press (Elsevier) eBook ISBN: 9780128184813, 2020 Pages 105-38.
18. Choudhury H, Gorain B, **Kesharwani P**. Chapter 4-Physiology of the biological barriers. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416
19. Zeeshan F, **Kesharwani P**. Chapter 8-From the nose to the brain, nanomedicine drug delivery. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416
20. Sahoo D, Bandaru R, Samal SK, Naik R, Kumar P, **Kesharwani P**, Dandela R. Chapter 9-Oral drug delivery of nanomedicine. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416
21. Gorain B, Patro S, Choudhury H, **Kesharwani P**. Chapter 10- Nanomedicine for inflammatory bowel disease. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416
22. Shukla R, Mishra P, Ujjwal RR, **Kesharwani P**. Chapter 13-Electrospun nanofibers for wound healing. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416
23. Shukla R, Handa M, Vasdev N, Singh DP, **Kesharwani P**. Chapter 15-Nanomedicine in pain management. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416

24. Kamble OS, Sanket AS, Samal SK, Dubey SK, **Kesharwani P**, Dandela R. Chapter 16-Advances in transdermal delivery of nanomedicine. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416
25. Singh S, Devi L, Molugulu N, **Kesharwani P**. Chapter 20-Regulatory pathway to introduce a nanomedicine product in the market at international level. Theory and Applications of Nonparenteral Nanomedicines. 1st Edition. Paperback ISBN: 9780128204665, Imprint: Academic Press, Published Date: 1st September 2020, Page Count: 416
26. Choudhury H, SP Sisinthy, Gorain B, **Kesharwani P**. Chapter 1 - History and introduction of dendrimers. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) ISBN-10 : 0128212500, ISBN-13 : 978-0128212509 Pages 1-14.
27. Bandarua R, Sanket SA, Rekha S, Kamble O, Dewangan RP, **Kesharwani P**, Samal SK, Dandela R. Chapter 5 - Biological interaction of dendrimers. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) eISBN- 9780128212516, Pages 63-74.
28. Gawande V, Choudhury H, **Kesharwani P**. Chapter 6 - Dendrimer nomenclature and synthesis methods. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) ISBN-10 : 0128212500, ISBN-13 : 978-0128212509 Pages 75-94.
29. Jain K, **Kesharwani P**. Jain NK. Chapter 7 - Types of dendrimers **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) ISBN-10 : 0128212500, ISBN-13 : 978-0128212509 Pages 95-123.
30. Kumbhar SA, Gorain B, Choudhury H, **Kesharwani P**. Chapter 9 - Safety and toxicity issues of dendrimers. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) ISBN-10 : 0128212500, ISBN-13 : 978-0128212509 Pages 143-162.
31. Kokare CR, Khot SV, Gorain B, **Kesharwani P**. Chapter 8 - Characterization of dendrimers. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) ISBN-10 : 0128212500, ISBN-13 : 978-0128212509 Pages 125-141.
32. Gorain B, Pandey M, Choudhury H, **Kesharwani P**. Chapter 15 - Dendrimer for solubility enhancement. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) ISBN-10 : 0128212500, ISBN-13 : 978-0128212509 Pages 273-283.
33. Singh S, Singh G, Sehrawat S, Rawat P, Molugulu N, Singh V, Ahmed FJ, **Kesharwani P**. Chapter 25 - Conclusion and future considerations of dendrimers. **Kesharwani P (Editor)**. Dendrimer-Based Nanotherapeutics. Publisher : Academic Press Inc (19 April 2021) ISBN-10 : 0128212500, ISBN-13 : 978-0128212509 Pages 449-458.
34. Bandaru R, Sahoo D, Naik R, Kesharwani P, Dandela R. Chapter 1. Pathogenesis, biology, and immunology of tuberculosis. Kesharwani P (Editor). Nanotechnology Based Approaches for Tuberculosis Treatment. Elsevier, Academic Press, eBook ISBN: 9780128226117, Paperback ISBN: 9780128198117, 2020 Pages 1-25.
35. Singh S, Dhankar N, Garg AK, Kesharwani P. Chapter 2. Tuberculosis: introduction, drug regimens, and multidrug-resistance. Kesharwani P (Editor). Nanotechnology Based Approaches for Tuberculosis Treatment. Elsevier, Academic Press, ISBN-10: 0128198117, ISBN-13: 978-0128198117, 2020 Pages 27-36.
36. Shukla R, Sethi A, Handa M, Mohan M, Kesharwani P, Tripathi PK. Chapter 10. Dendrimer-based drug delivery systems for tuberculosis treatment. Kesharwani P (Editor). Nanotechnology Based Approaches for Tuberculosis Treatment. Elsevier, Academic Press, ISBN-10: 0128198117, ISBN-13: 978-0128198117, 2020 Pages 163-174.
37. Gorain B, Choudhury H, Patro S, Kesharwani P. Chapter 11. Polymeric micelle-based drug delivery systems for tuberculosis treatment. Kesharwani P (Editor). Nanotechnology Based Approaches for Tuberculosis Treatment. Elsevier, Academic Press, ISBN-10: 0128198117, ISBN-13: 978-0128198117, 2020 Pages 175-191.
38. Choudhury H, Gorain B, Pandey M, Nirmal J, **Kesharwani P**. Chapter 4 - Surface engineering of nanoparticles for imparting multifunctionality. Pages 181-210. Nanoparticle Therapeutics:

Production Technologies, Types of Nanoparticles, and Regulatory Aspects, (January 2022). ISBN-10 : 0128207574, ISBN-13 : 978-0128207574.

39. Kakoty V, Sarathlal KC, Pandey M, Dubey SK, **Kesharwani P**, Taliyan R. Chapter 18 - Biological toxicity of nanoparticles. Pages 603-628. Nanoparticle Therapeutics: Production Technologies, Types of Nanoparticles, and Regulatory Aspects, January 2022, ISBN-10 : 0128207574, ISBN-13 : 978-0128207574.
40. SR Rout, K Gowtham, A. Sheikh, S. Parvez, R. Dandela, **P. Kesharwani***. Chapter 15 - Recent advances and future prospective of hybrid drug delivery systems. Hybrid Nanomaterials for Drug Delivery, Woodhead Publishing Series in Biomaterials, January 2022, Pages 357-374
41. K. Gowtham, A Kar, SR Rout, A Sheikh, S. Talegaonkar, **P. Kesharwani***, R Dandela. Chapter 6 - Hybrid chitosan-based nanoparticulate systems for drug delivery. Hybrid Nanomaterials for Drug Delivery. Woodhead Publishing Series in Biomaterials, January 2022, Pages 129-164
42. H Marwah, S. Khare, P. Rawat, S. Singh, **P. Kesharwani***, MS Alam, H Hamid, S Arora. Chapter 14 - Strengths, limitations, and regulatory aspects of hybrid drug delivery systems. Hybrid Nanomaterials for Drug Delivery, Woodhead Publishing Series in Biomaterials, January 2022, Pages 339-355
43. S Singh, H Marwah, P. Rawat, S. Awasthi, L. Singh, H. Rajak, **P. Kesharwani***. Chapter 4 - Hybrid nanogel systems for drug delivery. Hybrid Nanomaterials for Drug Delivery, Woodhead Publishing Series in Biomaterials, January 2022, Pages 85-100
44. H. Marwah, S. Singh, **P. Kesharwani***, S Arora. Chapter 10 - Dendrimer nanohybrid systems for drug delivery. Hybrid Nanomaterials for Drug Delivery, Woodhead Publishing Series in Biomaterials, January 2022, Pages 245-268
45. V Singh, A Sheikh, H Rajak, S Talegaonkar, H Hamid, MS Alam, **P Kesharwani***. Chapter 5: Combination drug delivery approaches in rheumatoid arthritis. **Kesharwani P (Editor).** Combination Drug Delivery Approach as an Effective Therapy for Various Diseases. 1st Edition - March 27, 2022. Paperback ISBN: 9780323858731; eBook ISBN: 9780323858762. Pages: 81-106.
46. G. Kenguva, S Rekha Rout, R Bandaru, R Dandela, A Sahebkar, **P Kesharwani***. Chapter 7: Combination drug delivery approaches for viral infections. **Kesharwani P (Editor).** Combination Drug Delivery Approach as an Effective Therapy for Various Diseases. 1st Edition - March 27, 2022. Paperback ISBN: 9780323858731; eBook ISBN: 9780323858762. Pages: 129-147.
47. G G. Kenguva, R Bandaru, SR Rout, K Greish, **P Kesharwani***, R Dandela. Chapter 10: Combination drug delivery approaches for cancer therapy. **Kesharwani P (Editor).** Combination Drug Delivery Approach as an Effective Therapy for Various Diseases. 1st Edition - March 27, 2022. Paperback ISBN: 9780323858731; eBook ISBN: 9780323858762. Pages: 213-237.
48. SR Rout, G Kenguva, V Singh, S Talegaonkar, **P Kesharwani***, R Dandela. Chapter 12: Combination of anticancer drugs with microRNA as cancer therapeutics. **Kesharwani P (Editor).** Combination Drug Delivery Approach as an Effective Therapy for Various Diseases. 1st Edition - March 27, 2022. Paperback ISBN: 9780323858731; eBook ISBN: 9780323858762. Pages: 273-295.
49. D. Sharma, S. Singh, P. Kumar, G.K. Jain, G. Aggarwal, W.H. Almalki, P. Kesharwani, Mechanisms of photodynamic therapy, Nanomater. Photodyn. Ther. (2023) 41–54. https://doi.org/10.1016/B978-0-323-85595-2.00017-7.
50. S. Parab, P.K. Achalla, N. Yanamandala, G. Singhvi, P. Kesharwani, S.K. Dubey, Sensitizers in photodynamic therapy, Nanomater. Photodyn. Ther. (2023) 81–103. https://doi.org/10.1016/B978-0-323-85595-2.00002-5.
51. A. Dey, P. Kesharwani, S.K. Dubey, Actively targeted nanoparticles in photodynamic therapy, Nanomater. Photodyn. Ther. (2023) 261–279. https://doi.org/10.1016/B978-0-323-85595-2.00014-1.
52. S.R. Rout, R. Bandaru, G. Kenguva, N. Hasan, M.S. Alam, R. Shukla, W. H. Almalki, P. Kesharwani, R. Dandela, Dendrimers in photodynamic therapy, Nanomater. Photodyn. Ther. (2023) 281–305. https://doi.org/10.1016/B978-0-323-85595-2.00004-9.
53. A. Dey, P. Kesharwani, S.K. Dubey, Photodynamic therapy in cosmetics, Nanomater. Photodyn. Ther. (2023) 441–458. https://doi.org/10.1016/B978-0-323-85595-2.00016-5.

54. D. Sharma, S.R. Rout, G. Kenguva, M. Khatravath, G.K. Jain, G. Aggarwal, P. Kesharwani, R. Dandela, PLGA-based nanoparticles as regenerative medicine, Poly(Lactic-Co-Glycolic Acid) Nanoparticles Drug Deliv. (2023) 335–356. https://doi.org/10.1016/B978-0-323-91215-0.00011-X.
55. S.R. Rout, G. Kenguva, D. Sharma, A. Sahebkar, V. Aeri, P. Kesharwani, R. Dandela, Gene therapy using PLGA nanoparticles, Poly(Lactic-Co-Glycolic Acid) Nanoparticles Drug Deliv. (2023) 393–414. https://doi.org/10.1016/B978-0-323-91215-0.00009-1.
56. S. Kumari, J.S. Bhardwaj, S.S. Kharavtekar, D. Grewal, S.G. Ray, A. Bhardwaj, S.K. Dubey, P. Kesharwani, T. Arora, R. Taliyan, Futuristic aspect of nanocarriers on targeted delivery for dementia, Nanomedicine-Based Approaches Treat. Dement. (2023) 265–294. https://doi.org/10.1016/B978-0-12-824331-2.00005-4.
57. P.C. Guest, P. Kesharwani, A.E. Butler, A. Sahebkar, The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern, (2023) 3–26. https://doi.org/10.1007/978-3-031-28012-2_1.
58. A.P. Thakare, A. Kar, L. Giri, W.H. Almalki, M.R. Pichika, G. Gupta, P. Kesharwani, R. Dandela, Silver nanoparticles in wound therapy and tissue regeneration, Silver Nanoparticles Drug Deliv. (2024) 165–190. https://doi.org/10.1016/B978-0-443-15343-3.00015-2.
59. K. Prakash, K.R. Manu, S.R. Rout, W.H. Almalki, P. Kumar, A. Sahebkar, P. Kesharwani, R. Dandela, History, introduction, and physiochemical properties of gold nanoparticles, Gold Nanoparticles Drug Deliv. (2024) 3–30. https://doi.org/10.1016/B978-0-443-19061-2.00014-6.
60. G. Kaur, J. Rath, S.R. Rout, W.H. Almalki, A. Sahebkar, M.S. Alam, P. Kesharwani, R. Dandela, Conclusion and future perspective of gold nanoparticles, Gold Nanoparticles Drug Deliv. (2024) 511–526. https://doi.org/10.1016/B978-0-443-19061-2.00009-2.
61. K.R. Manu, K.G. Abishek, S.R. Rout, W.H. Almalki, H.N. Yadav, A. Sahebkar, P. Kesharwani, R. Dandela, Gold nanoparticles as a recent nanocarrier against HIV/AIDS, Gold Nanoparticles Drug Deliv. (2024) 305–329. https://doi.org/10.1016/B978-0-443-19061-2.00015-8.
62. A. Kar, L. Giri, W.H. Almalki, S. Singh, A. Sahebkar, P. Kesharwani, R. Dandela, Conclusion and future prospective of silver nanoparticles, Silver Nanoparticles Drug Deliv. (2024) 433–452. https://doi.org/10.1016/B978-0-443-15343-3.00001-2.
63. N.-A. Lashgari, N.M. Roudsari, H.S. Shamsnia, Z. Koolivand, S. Momtaz, A.H. Abdolghaffari, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Where do we stand? Insight on patented products and those under clinical trials, Adv. Antiparasit. Ther. Drug Deliv. (2024) 355–381. https://doi.org/10.1016/B978-0-443-15178-1.00009-2.
64. L. Dehghani, A.M. Gorabi, A. Jalili, A. Rahbarghazi, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Challenges and opportunities in antiparasitic drug discovery and delivery, Adv. Antiparasit. Ther. Drug Deliv. (2024) 383–390. https://doi.org/10.1016/B978-0-443-15178-1.00001-8.
65. A.M. Gorabi, A. Rahbarghazi, R. Rahbarghazi, S. Fathi-Karkan, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Microneedles in antiparasitic drug delivery applications, Adv. Antiparasit. Ther. Drug Deliv. (2024) 107–115. https://doi.org/10.1016/B978-0-443-15178-1.00012-2.
66. S. Nasirizadeh, P. Kesharwani, A. Sahebkar, Antiparasitic drugs: a definition and scope, Adv. Antiparasit. Ther. Drug Deliv. (2024) 91–96. https://doi.org/10.1016/B978-0-443-15178-1.00013-4.
67. H.S. Shamsnia, D. Khayatan, A.S. Kashani, M. Roustaei, Y. Hosseini, L.M. Shalmani, S. Momtaz, A.H. Abdolghaffari, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Nanomedicine for parasitic helminth infections, Adv. Antiparasit. Ther. Drug Deliv. (2024) 135–152. https://doi.org/10.1016/B978-0-443-15178-1.00002-X.
68. K.R. Manu, G. Kaur, A. Kar, L. Giri, W.H. Almalki, N. Gupta, A. Sahebkar, P. Kesharwani, R. Dandela, Future prospect of nano-based drug delivery approaches against pancreatic cancer and expected pitfalls of the technology, Recent Adv. Nanocarriers Pancreat. Cancer Ther. (2024) 419–442. https://doi.org/10.1016/B978-0-443-19142-8.00007-3.
69. F. Shahdadian, M. Bagherniya, G. Askari, P. Kesharwani, R. Rajendram, A. Sahebkar, Barberry (Berberis vulgaris) : Composition and Use of Extracts in Cancer Studies, Anc. Tradit. Foods,

Plants, Herbs Spices Used Cancer. (2023) 113–128. https://doi.org/10.1201/9781003260028-11. (11 October 2023).
70. N. Parveen, V. Aeri, W.H. Almalki, A. Sahebkar, P. Kesharwani*, Conclusion and Future Perspectives of Phytonanotechnology, Adv. Phytonanotechnology Treat. Var. Dis. (2023) 357–371. https://doi.org/10.1201/9781003231721-15
71. U. Rehman, A. Sahebkar, N. Hasan, G.K. Jain, W.H. Almalki, P. Kesharwani, Transdermal drug absorption: Mathematical modelling, Nanocosmetics Deliv. Approaches, Appl. Regul. Asp. (2023) 17–30. https://doi.org/10.1201/9781003319146-2/.
72. N. Parveen, V. Aeri, W.H. Almalki, A. Sahebkar, P. Kesharwani, Conclusion and Future Perspectives of Phytonanotechnology, Adv. Phytonanotechnology Treat. Var. Dis. (2023) 357–371. https://doi.org/10.1201/9781003231721-15.
73. K. Prakash, K.R. Manu, S.R. Rout, W.H. Almalki, P. Kumar, A. Sahebkar, P. Kesharwani, R. Dandela, History, introduction, and physiochemical properties of gold nanoparticles, Gold Nanoparticles Drug Deliv. (2024) 3–30. https://doi.org/10.1016/B978-0-443-19061-2.00014-6.
74. K.R. Manu, K.G. Abishek, S.R. Rout, W.H. Almalki, H.N. Yadav, A. Sahebkar, P. Kesharwani, R. Dandela, Gold nanoparticles as a recent nanocarrier against HIV/AIDS, Gold Nanoparticles Drug Deliv. (2024) 305–329. https://doi.org/10.1016/B978-0-443-19061-2.00015-8.
75. G. Kaur, J. Rath, S.R. Rout, W.H. Almalki, A. Sahebkar, M.S. Alam, P. Kesharwani, R. Dandela, Conclusion and future perspective of gold nanoparticles, Gold Nanoparticles Drug Deliv. (2024) 511–526. https://doi.org/10.1016/B978-0-443-19061-2.00009-2.
76. S. Nasirizadeh, P. Kesharwani, A. Sahebkar, Antiparasitic drugs: a definition and scope, Adv. Antiparasit. Ther. Drug Deliv. (2024) 91–96. https://doi.org/10.1016/B978-0-443-15178-1.00013-4.
77. A.M. Gorabi, A. Rahbarghazi, R. Rahbarghazi, S. Fathi-Karkan, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Microneedles in antiparasitic drug delivery applications, Adv. Antiparasit. Ther. Drug Deliv. (2024) 107–115. https://doi.org/10.1016/B978-0-443-15178-1.00012-2.
78. H.S. Shamsnia, D. Khayatan, A.S. Kashani, M. Roustaei, Y. Hosseini, L.M. Shalmani, S. Momtaz, A.H. Abdolghaffari, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Nanomedicine for parasitic helminth infections, Adv. Antiparasit. Ther. Drug Deliv. (2024) 135–152. https://doi.org/10.1016/B978-0-443-15178-1.00002-X.
79. N.-A. Lashgari, N.M. Roudsari, H.S. Shamsnia, Z. Koolivand, S. Momtaz, A.H. Abdolghaffari, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Where do we stand? Insight on patented products and those under clinical trials, Adv. Antiparasit. Ther. Drug Deliv. (2024) 355–381. https://doi.org/10.1016/B978-0-443-15178-1.00009-2.
80. L. Dehghani, A.M. Gorabi, A. Jalili, A. Rahbarghazi, T. Jamialahmadi, P. Kesharwani, A. Sahebkar, Challenges and opportunities in antiparasitic drug discovery and delivery, Adv. Antiparasit. Ther. Drug Deliv. (2024) 383–390. https://doi.org/10.1016/B978-0-443-15178-1.00001-8.
81. A.P. Thakare, A. Kar, L. Giri, W.H. Almalki, M.R. Pichika, G. Gupta, P. Kesharwani, R. Dandela, Silver nanoparticles in wound therapy and tissue regeneration, Silver Nanoparticles Drug Deliv. (2024) 165–190. https://doi.org/10.1016/B978-0-443-15343-3.00015-2.
82. A. Kar, L. Giri, W.H. Almalki, S. Singh, A. Sahebkar, P. Kesharwani, R. Dandela, Conclusion and future prospective of silver nanoparticles, Silver Nanoparticles Drug Deliv. (2024) 433–452. https://doi.org/10.1016/B978-0-443-15343-3.00001-2.
83. K.R. Manu, G. Kaur, A. Kar, L. Giri, W.H. Almalki, N. Gupta, A. Sahebkar, P. Kesharwani, R. Dandela, Future prospect of nano-based drug delivery approaches against pancreatic cancer and

expected pitfalls of the technology, Recent Adv. Nanocarriers Pancreat. Cancer Ther. (2024) 419–442. https://doi.org/10.1016/B978-0-443-19142-8.00007-3.

Any other Information:

In brief, I would like to apprise that at the young age of 39, I have received many international and national prestigious awards such as "USERN Laureates - 2023" in Biological Sciences [among more than 90,000 applications from all over the world and applications have been carefully reviewed by more than 70 top 1% well-known scientists], "Best poster award at Wayne State University USA – 2016", and most Prestigious "Ramanujan Fellowship (SERB-DST)". I have also been listed in the "WORLD'S TOP 2% SCIENTISTS" list in year 2020, 2021, 2022 and 2023 in the field of "Pharmacology & Pharmacy" published by Stanford University, USA.

I have also received 6 research grants from various funding bodies [four from ICMR, one from SERB-DST and one from UGC]. I am the only candidate who has joined Jamia Hamdard, New Delhi with 5 advanced salary increments based upon my academic and research achievements.

From best of my knowledge, I am the first candidate from pharmaceutical background, who has been awarded the most Prestigious "Ramanujan Fellowship".

I have published more than 400 articles in well reputed high impact factor journals and more than 25 internaitonal books as an Editor. My cumulative impact factor (IF) is 4496.217, total citations are 22784, h-index-79 & i-10 index is 329. I have more than 25 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072).

In summary, my research is at the cutting edge of nanomedicine, in developing and exploring the utility of use-inspired polymeric biomaterials and nanomaterials with the potential to revolutionize the field of drug discovery based on nanotechnology.